Document:

EX-4.4

 Exhibit 4.4 

WARRANT AGREEMENT 
 THIS
WARRANT AGREEMENT (this “Agreement”), dated as of [                ], 2020, is by and between Altitude Acquisition Corp., a Delaware corporation
(the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (in such capacity, the “Warrant Agent”, and also referred to herein as the
“Transfer Agent”). 
 WHEREAS, the Company is engaged in an initial public offering (the
“Offering”) of units of the Company’s equity securities, each such unit comprised of one share of Class A common stock of the Company, par value $0.0001 per share (“Common Stock”), and one-third of one redeemable Public Warrant (as defined below) (the “Units”) and, in connection therewith, has determined to issue and deliver up to 10,000,000 warrants (or up to 11,500,000
warrants if the Over-allotment Option (as defined below) is exercised in full) to public investors in the Offering (the “Public Warrants”); 

WHEREAS, the Company has entered into that certain Private Placement Warrants Purchase Agreement (the “Sponsor Private Placement
Warrants Purchase Agreement”) with Altitude Acquisition Holdco LLC, a Delaware limited liability company (the “Sponsor”), pursuant to which the Sponsor agreed to purchase an aggregate of 5,333,333 warrants
simultaneously with the closing of the Offering bearing the legend set forth in Exhibit B hereto (the “Private Placement Warrants”) at a purchase price of $1.50 per Private Placement Warrant; 

WHEREAS, in order to finance the Company’s transaction costs in connection with an intended initial Business Combination (as defined
below), the Sponsor or an affiliate of the Sponsor or the Company’s officers and directors may, but are not obligated to, loan to the Company funds as the Company may require, of which up to $1,500,000 of such loans may be convertible into up
to an additional 1,000,000 warrants at a price of $1.50 per warrant (the “Working Capital Warrants”); 
 WHEREAS,
the Company has filed with the U.S. Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1, File
No. 333-249071 (the “Registration Statement”), and prospectus (the “Prospectus”), for the registration, under the Securities Act of 1933, as amended (the
“Securities Act”), of the Units, the Public Warrants and the Common Stock included in the Units; 
 WHEREAS,
following consummation of the Offering, the Company may issue additional warrants (the “Post-IPO Warrants” and, together with the Private Placement Warrants, the Working Capital
Warrants and the Public Warrants, the “Warrants”) in connection with, or following the consummation by the Company of, a Business Combination; 

WHEREAS, each whole Warrant entitles the holder thereof to purchase one share of Common Stock for $11.50 per whole share, subject to
adjustment as described herein. Only whole Warrants are exercisable. A holder of the Public Warrants will not be able to exercise any fraction of a Warrant; 

 WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the
Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants; 

WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and 

WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and
countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows: 

1.    Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company
for the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement. 

2.    Warrants. 

2.1    Form of Warrant. Each Warrant shall be issued in registered form only, and, if a physical certificate is
issued, shall be in substantially the form of Exhibit A hereto, the provisions of which are incorporated herein and shall be signed by, or bear the facsimile signature of, the Chairman of the Company’s board of directors (the
“Board”), President, Chief Executive Officer, Chief Financial Officer, Secretary or other principal officer of the Company. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased
to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance. All of the Public Warrants shall initially be
represented by one or more book-entry certificates (each, a “Book-Entry Warrant Certificate”). 

2.2    Effect of Countersignature. If a physical certificate is issued, unless and until countersigned by the
Warrant Agent pursuant to this Agreement, a Warrant certificate shall be invalid and of no effect and may not be exercised by the holder thereof. 

2.3    Registration. 

2.3.1    Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”)
for the registration of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such
denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. All of the Public 

  
 2 

 
Warrants shall initially be represented by one or more Book-Entry Warrant Certificates deposited with The Depository Trust Company (the “Depositary”) and registered in the
name of Cede & Co., a nominee of the Depositary. Ownership of beneficial interests in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its
nominee for each Book-Entry Warrant Certificate, or (ii) institutions that have accounts with the Depositary (each such institution, with respect to a Warrant in its account, a “Participant”). 

If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent
regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide
written instructions to the Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form
evidencing such Warrants (“Definitive Warrant Certificate”). Such Definitive Warrant Certificate shall be in the form annexed hereto as Exhibit A, with appropriate insertions, modifications and omissions, as provided
above. 
 2.3.2    Registered Holder. Prior to due presentment for registration of transfer of any Warrant, the
Company and the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”) as the absolute owner of such Warrant and of each Warrant represented
thereby (notwithstanding any notation of ownership or other writing on a Definitive Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the
Company nor the Warrant Agent shall be affected by any notice to the contrary. 
 2.4    Detachability of
Warrants. The Common Stock and Public Warrants comprising the Units shall begin separate trading on the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday, on
which banks in New York City are generally open for normal business (a “Business Day”), then on the immediately succeeding Business Day following such date, or earlier (the “Detachment
Date”) with the consent of Cantor Fitzgerald & Co., as representative of the several underwriters, but in no event shall the Common Stock and the Public Warrants comprising the Units be separately traded until
(A) the Company has filed a current report on Form 8-K with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering, including the
proceeds received by the Company from the exercise by the underwriters of their right to purchase additional Units in the Offering (the “Over-allotment Option”), if the Over-allotment Option is exercised prior to the filing
of the Form 8-K, and (B) the Company issues a press release and files with the Commission a current report on Form 8-K announcing when such separate trading shall
begin. 
 2.5    Fractional Warrants. The Company shall not issue fractional Warrants other than as part of the
Units, each of which is comprised of one share of Common Stock and 

  
 3 

 
one-third of one Public Warrant. If, upon the detachment of Public Warrants from Units or otherwise, a holder of Warrants would be entitled to receive a
fractional Warrant, the Company shall round down to the nearest whole number of Warrants to be issued to such holder. 

2.6    Private Placement Warrants and Working Capital Warrants. The Private Placement Warrants and the Working
Capital Warrants shall be identical to the Public Warrants, except that so long as they are held by the Sponsor, or any of their Permitted Transferees (as defined below), as applicable, the Private Placement Warrants and the Working Capital
Warrants: (i) may be exercised for cash or on a cashless basis, pursuant to subsection 3.3.1(c) hereof, (ii) may not be transferred, assigned or sold until the date that is thirty (30) days after the completion by the Company
of an initial Business Combination (as defined below), and (iii) shall not be redeemable by the Company; provided, however, that in the case of (ii), the Private Placement Warrants and the Working Capital Warrants and any shares of
Common Stock held by the Sponsor, or any officers or directors of the Company, or any Permitted Transferees, as applicable, and issued upon exercise of the Private Placement Warrants and the Working Capital Warrants may be transferred by the holders
thereof: 
 (a)    to the Company’s officers or directors, any affiliate or family member of any of the
Company’s officers or directors, any affiliate of the Sponsor or to any members of the Sponsor or any of their affiliates; 

(b)    in the case of an individual, by gift to a member of such individual’s immediate family or to a trust, the
beneficiary of which is a member of such individual’s immediate family, an affiliate of such individual or to a charitable organization; 

(c)    in the case of an individual, by virtue of laws of descent and distribution upon death of such person; 

(d)    in the case of an individual, pursuant to a qualified domestic relations order; 

(e)    by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in
connection with the consummation of an initial Business Combination at prices no greater than the price at which the Warrants were originally purchased; 

(f)    by virtue of the laws of the State of Delaware or the limited liability company agreement of the Sponsor upon
dissolution of the Sponsor; 
 (g)    in the event of the Company’s liquidation prior to the consummation of a
Business Combination; or 
 (h)    in the event that, subsequent to the consummation of a Business Combination, the
Company completes a liquidation, merger, share exchange or other similar transaction which results in all of the Company’s stockholders having the right to exchange their 

  
 4 

 
shares of Common Stock for cash, securities or other property; provided, however, that, in the case of clauses (a) through (f), these transferees (the “Permitted
Transferees”) enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this Agreement and the other restrictions contained in the letter agreement, dated as of the date hereof, by and among
the Company, the Sponsor and the Company’s officers and directors. 
 2.7    Working Capital Warrants. Each
of the Working Capital Warrants shall be identical to the Private Placement Warrants. 
 2.8    Post-IPO Warrants
The Post-IPO Warrants, when and if issued, shall have the same terms and be in the same form as the Public Warrants except as may be agreed upon by the Company. 

3.    Terms and Exercise of Warrants. 

3.1    Warrant Price. Each Warrant shall entitle the Registered Holder thereof, subject to the provisions of such
Warrant and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of this
Section 3.1. The term “Warrant Price” as used in this Agreement shall mean the price per share at which shares of Common Stock may be purchased at the time a Warrant is exercised. The Company in its sole discretion may lower
the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days, provided, that the Company shall provide at least twenty (20) days prior written notice of such
reduction to Registered Holders of the Warrants and, provided further that any such reduction shall be identical among all of the Warrants. 

3.2    Duration of Warrants. A Warrant may be exercised only during the period (the “Exercise
Period”) commencing on the later of: (i) the date that is thirty (30) days after the first date on which the Company completes a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar
business combination, involving the Company and one or more businesses (a “Business Combination”), and (ii) the date that is twelve (12) months from the date of the closing of the Offering, and terminating on the
earlier to occur of: (i) at 5:00 p.m., New York City time on the date that is five (5) years after the date on which the Company completes its initial Business Combination, (ii) the liquidation of the Company and (iii) other than
with respect to the Private Placement Warrants and the Working Capital Warrants then held by the Sponsor or any officers or directors of the Company, or any of their Permitted Transferees as provided in Section 6.1, the Redemption Date
(as defined below) as provided in Section 6.2 hereof (the “Expiration Date”); provided, however, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set
forth in subsection 3.3.2 below, with respect to an effective registration statement. Except with respect to the right to receive the Redemption Price (as defined below) in the event of a redemption (as set forth in Section 6 hereof),
each outstanding Warrant (other than a Private Placement Warrant or a Working Capital Warrant held by the Sponsor or any officers or directors of the Company, or their Permitted Transferees, in the event of a redemption for cash) not exercised on or
before the Expiration Date 

  
 5 

 
shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole
discretion may extend the duration of the Warrants by delaying the Expiration Date; provided that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and,
provided further that any such extension shall be identical in duration among all the Warrants. 
 3.3    Exercise of
Warrants. 
 3.3.1    Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant may be
exercised by the Registered Holder thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate,
the Warrants to be exercised (the “Book-Entry Warrants”) on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant Agent to the Depositary
from time to time, (ii) an election to purchase (“Election to Purchase”) shares of Common Stock pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse of the
Definitive Warrant Certificate or, in the case of a Book-Entry Warrant Certificate, properly delivered by the Participant in accordance with the Depositary’s procedures, and (iii) payment in full of the Warrant Price for each full share of
Common Stock as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the shares of Common Stock and the issuance of such shares of Common Stock, as
follows: 
 (a)    in lawful money of the United States, in good certified check or good bank draft payable to the
order of the Warrant Agent or by wire transfer of immediately available funds; 
 (b)    in the event of a redemption
pursuant to Section 6 hereof in which the Company’s board of directors (the “Board”) has elected to require all holders of the Warrants to exercise such Warrants on a “cashless basis,” by
surrendering the Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market
Value”, as defined in this subsection 3.3.1(b), over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this subsection 3.3.1(b) and Section 6.3, the “Fair Market Value” shall
mean the average closing price of the Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of the Warrants, pursuant to Section 6
hereof; 
 (c)    with respect to any Private Placement Warrant or Working Capital Warrant, so long as such Private
Placement Warrant or Working Capital Warrant is held by either the Sponsor or any officer or director of the Company, or their Permitted Transferees, by surrendering the Warrants for that number of shares of Common Stock equal to the quotient
obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value”, as defined in this subsection

  
 6 

 
3.3.1(c), over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this subsection 3.3.1(c), the “Fair Market Value” shall mean the average closing
price of the Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which notice of exercise of the Private Placement Warrant or Working Capital Warrant is sent to the Warrant Agent; or 

(d)    as provided in Section 7.4 hereof. 

3.3.2    Issuance of Shares of Common Stock on Exercise. As soon as practicable after the exercise of any Warrant
and the clearance of the funds in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1 (a)), the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the
number of full shares of Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned
Warrant, as applicable, for the number of shares of Common Stock as to which such Warrant shall not have been exercised. If fewer than all the Warrants evidenced by a Book-Entry Warrant Certificate are exercised, a notation shall be made to the
records maintained by the Depositary, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants remaining after such exercise. Notwithstanding the foregoing, the Company shall not
be obligated to deliver any shares of Common Stock pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock
underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company’s satisfying its obligations under Section 7.4. No Warrant shall be exercisable and the Company shall not be obligated to
issue shares of Common Stock upon exercise of a Warrant unless the Common Stock issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the state of
residence of the Registered Holder of the Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant
and such Warrant may have no value and expire worthless, in which case the purchaser of a Unit containing such Public Warrants shall have paid the full purchase price for the Unit solely for the shares of Common Stock underlying such Unit. In no
event will the Company be required to net cash settle the Warrant exercise. The Company may require holders of Public Warrants to settle the Warrant on a “cashless basis” pursuant to Section 7.4. If, by reason of any exercise
of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share of Common Stock, the Company shall round down to the nearest whole number, the
number of shares of Common Stock to be issued to such holder. 
 3.3.3    Valid Issuance. All shares of Common
Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and non-assessable. 

  
 7 

 3.3.4    Date of Issuance. Each person in whose name any
book-entry position or certificate, as applicable, for shares of Common Stock is issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date on which the Warrant, or book-entry position
representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date
when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have become the holder of such shares of Common Stock at the close of business on the next succeeding date on which the
share transfer books or book-entry system are open. 
 3.3.5    Maximum Percentage. A holder of a Warrant may
notify the Company in writing in the event it elects to be subject to the provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such
election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise,
such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify)(the “Maximum
Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such person and its
affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock that would be issuable upon
(x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company
beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein.
Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent
Annual Report on Form 10-K, Quarterly Report on Form 10-Q, current report on Form 8-K or other public filing with the Commission
as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the
written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By
written notice to the Company, the holder of a Warrant may from time to time 

  
 8 

 
increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective
until the sixty-first (61st) day after such notice is delivered to the Company. 
 4.    Adjustments. 

4.1    Stock Dividends. 

4.1.1    Split-Ups. If after the date hereof, and subject to the provisions
of Section 4.6 below, the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock or other
similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be increased in proportion to such
increase in the outstanding shares of Common Stock. A rights offering to holders of the Common Stock entitling holders to purchase shares of Common Stock at a price less than the “Fair Market Value” (as defined below) shall be deemed a
stock dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are
convertible into or exercisable for the Common Stock) multiplied by (ii) one (1) minus the quotient of (x) the price per share of Common Stock paid in such rights offering and divided by (y) the Fair Market Value. For purposes of this
subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Common Stock, in determining the price payable for Common Stock, there shall be taken into account any consideration received for such rights,
as well as any additional amount payable upon exercise or conversion and (ii) “Fair Market Value” means the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading day
prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. 

4.1.2    Extraordinary Dividends. If the Company, at any time while the Warrants are outstanding and unexpired,
shall pay a dividend or make a distribution in cash, securities or other assets to the holders of the Common Stock on account of such shares of Common Stock (or other shares of the Company’s capital stock into which the Warrants are
convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of the holders of the Common Stock in connection with a proposed initial
Business Combination, (d) to satisfy the redemption rights of the holders of Common Stock in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (as amended from time to time, the
“Charter”) to modify the substance or timing of the Company’s obligation to redeem 100% of the shares of Common Stock included in the Units sold in the Offering if the Company does not complete the Business Combination
within the period set forth in the Charter or with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, or to provide for redemption in
connection with a Business Combination or (e) in connection with the redemption of public shares of Common Stock included in the Units sold in the Offering upon the failure of the Company to complete its initial Business Combination and any

  
 9 

 
subsequent distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an “Extraordinary
Dividend”), then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined by the Board, in good faith) of any
securities or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend. For purposes of this subsection 4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash distribution
which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid on the Common Stock during the 365-day period ending on the date of declaration of
such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant
Price or to the number of shares of Common Stock issuable on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Units in the Offering). 

4.2    Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 4.6
hereof, the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation,
combination, reverse stock split, reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock. 

4.3    Adjustments in Warrant Price. 

4.3.1    Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as
provided in subsection 4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which
shall be the number of shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of shares of Common Stock so purchasable immediately
thereafter. 
 4.3.2    If (x) the Company issues additional shares of Common Stock or equity-linked securities
for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Common Stock (with such issue price or effective issue price to be determined
in good faith by the Board and, in the case of any such issuance to the initial stockholders (as defined in the Prospectus) or their affiliates, without taking into account any shares of Class B Common Stock (as defined below) held by such
stockholders or their affiliates, as applicable, prior to such issuance (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest
thereon, available for funding the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Common Stock during the 20 trading day period starting on the trading day prior to the day on which
the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the Warrant Price shall be adjusted (to the nearest 

  
 10 

 
cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the last sales price of the Common Stock that triggers the Company’s right to redeem the Warrants
pursuant to Section 6.1 below shall be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. 

4.4    Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the
outstanding shares of Common Stock (other than a change under subsections 4.1.1 or 4.1.2 or Section 4.2 hereof or that solely affects the par value of such shares of Common Stock), or in the case of any merger or
consolidation of the Company with or into another entity or conversion of the Company as another entity (other than a consolidation or merger in which the Company is the continuing corporation (and is not a subsidiary of another entity whose
stockholders did not own all or substantially all of the Common Stock of the Company in substantially the same proportions immediately before such transaction) and that does not result in any reclassification or reorganization of the outstanding
shares of Common Stock), or in the case of any sale or conveyance to another entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the holders of the
Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the shares of Common Stock of the Company immediately theretofore purchasable and receivable
upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution
following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such event (the “Alternative Issuance”); provided,
however, that (i) if the holders of the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of
securities, cash or other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share by the holders of the Common Stock in such
consolidation or merger that affirmatively make such election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders of the Common Stock (other than a tender, exchange or redemption offer made by
the Company in connection with redemption rights held by stockholders of the Company as provided for in the Charter or as a result of the redemption of shares of Common Stock by the Company if a proposed initial Business Combination is presented to
the stockholders of the Company for approval) under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule
13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule
12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor rule)) more than 50% of the outstanding shares of Common Stock, the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the highest amount of
cash, securities or other property to which such holder would actually have been entitled as a 

  
 11 

 
stockholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the Common Stock held by such holder had been
purchased pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section 4;
provided further that if less than 70% of the consideration receivable by the holders of the Common Stock in the applicable event is payable in the form of common stock in the successor entity that is listed for trading on a national
securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the
Registered Holder properly exercises the Warrant within thirty (30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form
8-K filed with the Commission, the Warrant Price shall be reduced by an amount (in dollars) equal to the difference (but in no event less than zero) of (i) the Warrant Price in effect prior to such
reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior
to the consummation of the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets (“Bloomberg”). 

For purposes of calculating such amount, (1) Section 6 of this Agreement shall be taken into account, (2) the price of
each share of Common Stock shall be the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event, (3) the assumed
volatility shall be the 90 day volatility obtained from the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event, and (4) the assumed risk-free interest rate shall
correspond to the U.S. Treasury rate for a period equal to the remaining term of the Warrant. “Per Share Consideration” means (i) if the consideration paid to holders of the Common Stock consists exclusively of cash, the
amount of such cash per share of Common Stock, and (ii) in all other cases, the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of
the applicable event. If any reclassification or reorganization also results in a change in shares of Common Stock covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3
and this Section 4.4. The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event
will the Warrant Price be reduced to less than the par value per share issuable upon exercise of the Warrant. 

4.5    Notices of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares of Common
Stock issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the increase or decrease, if any, in the number of shares of
Common Stock purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in Sections
4.1, 4.2, 4.3 or 4.4, the Company 

  
 12 

 
shall give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of the record date or the effective
date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event. 

4.6    No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company
shall not issue fractional shares of Common Stock upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive
a fractional interest in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to such holder. 

4.7    Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this
Section 4, and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares of Common Stock as is stated in the Warrants initially issued pursuant to this Agreement; provided, however, that
the Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange
or substitution for an outstanding Warrant or otherwise, may be in the form as so changed. 
 4.8    Other
Events. In case any event shall occur affecting the Company as to which none of the provisions of the preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants
in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment
banking or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate the intent and purpose of this
Section 4 and, if they determine that an adjustment is necessary, the terms of such adjustment. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion. 

4.9    No Adjustment. For the avoidance of doubt, no adjustment shall be made to the terms of the Warrants solely
as a result of an adjustment to the conversion ratio of the Company’s Class B common stock (the “Class B Common Stock”) into shares of Common Stock or the conversion of the shares of
Class B Common Stock into shares of Common Stock, in each case, pursuant to the Charter. 
 5.    Transfer and
Exchange of Warrants. 
 5.1    Registration of Transfer. The Warrant Agent shall register the transfer, from
time to time, of any outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of a certificated Warrant, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions
for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and 

  
 13 

 
the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time
upon request. 
 5.2    Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent,
together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered, representing an equal aggregate
number of Warrants; provided, however, that except as otherwise provided herein or in any Book-Entry Warrant Certificate or Definitive Warrant Certificate, each Book-Entry Warrant Certificate and Definitive Warrant Certificate may be
transferred only in whole and only to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further, however, that in the event that a Warrant surrendered for
transfer bears a restrictive legend (as in the case of the Private Placement Warrants and the Working Capital Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until the Warrant Agent has received
an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend. 

5.3    Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or
exchange which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units. 

5.4    Service Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 5.5    Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to
deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with
Warrants duly executed on behalf of the Company for such purpose. 
 5.6    Transfer of Warrants. Prior to the
Detachment Date, the Public Warrants may be transferred or exchanged only together with the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit. Furthermore, each
transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer of Warrants on
and after the Detachment Date. 
 6.    Redemption. 

6.1    Redemption of Warrants for Cash. Subject to Sections 6.4 hereof, not less than all of the outstanding
Warrants may be redeemed, at the option of the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in
Section 6.2 below, at the price 

  
 14 

 
of $0.01 per Warrant (the “Redemption Price”); provided that the closing price of the Common Stock reported has been at least $18.00 per share (subject to
adjustment in compliance with Section 4 hereof), on each of twenty (20) trading days within the thirty (30) trading-day period ending on the third Business Day prior to the date on which notice
of the redemption is given; provided further that there is an effective registration statement covering the shares of Common Stock issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.2 below) or the Company has elected to require the exercise of the Warrants on a “cashless basis” pursuant to subsection 3.3.1 and such
cashless exercise is exempt from registration under the Securities Act. 
 6.2    Date Fixed for, and Notice of,
Redemption. In the event that the Company elects to redeem all of the Warrants pursuant to Section 6.1, the Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be
mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date (such period, the “Redemption Period”) to the Registered Holders of the Warrants to be redeemed at
their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the Registered Holder received such notice. 

6.3    Exercise After Notice of Redemption. The Warrants may be exercised, for cash (or on a “cashless
basis” in accordance with subsection 3.3.1(b) of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to Section 6.2 hereof and prior to the Redemption Date. In the event that
the Company determines to require all holders of Warrants to exercise their Warrants on a “cashless basis” pursuant to subsection 3.3.1, the notice of redemption shall contain the information necessary to calculate the number of
shares of Common Stock to be received upon exercise of the Warrants, including the “Fair Market Value” (as such term is defined in subsection 3.3.1(b) hereof) in such case. On and after the Redemption Date, the record holder of the
Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price. 

6.4    Exclusion of Certain Warrants. The Company agrees that the redemption rights provided in
Section 6.1 shall not apply to the Private Placement Warrants, the Working Capital Warrants or the Post-IPO Warrants (if such Post-IPO Warrants provide that
they are non-redeemable by the Company) if at the time of the redemption such Private Placement Warrants, Working Capital Warrants or Post-IPO Warrants continue to be
held by the Sponsor or any Permitted Transferees, as applicable. However, once such Private Placement Warrants, Working Capital Warrants or Post-IPO Warrants are transferred (other than to Permitted
Transferees under Section 2.6), the Company may redeem the Private Placement Warrants, the Working Capital Warrants or the Post-IPO Warrants (if the Post-IPO
Warrants permit such redemption by their terms) pursuant to Section 6.1 hereof, provided that the criteria for redemption are met, including the opportunity of the holder of such Private Placement Warrants, Working Capital Warrants or Post-IPO Warrants to exercise the Private Placement Warrants, the Working Capital Warrants or the Post-IPO Warrants prior to redemption pursuant to Section 6.1.
The Private Placement Warrants, the Working Capital Warrants or the Post-IPO Warrants (if such Post-IPO Warrants provide that they are
non-redeemable by the Company) that are transferred to persons other than Permitted Transferees shall upon such transfer cease to be Private Placement Warrants, Working Capital Warrants or Post-IPO Warrants and shall become Public Warrants under this Agreement. 

  
 15 

 7.    Other Provisions Relating to Rights of Holders of Warrants.

 7.1    No Rights as Stockholder. A Warrant does not entitle the Registered Holder thereof to any of the rights
of a stockholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as stockholders in respect of the meetings of
stockholders or the election of directors of the Company or any other matter. 
 7.2    Lost, Stolen, Mutilated, or
Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company,
whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone. 

7.3    Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its
authorized but unissued shares of Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement. 

7.4    Registration of Common Stock; Cashless Exercise at Company’s Option. 

7.4.1    Registration of the Common Stock. The Company agrees that as soon as practicable, but in no event later
than fifteen (15) Business Days after the closing of its initial Business Combination, it shall use its best efforts to file with the Commission a registration statement registering, under the Securities Act, the issuance of the shares of
Common Stock issuable upon exercise of the Warrants. The Company shall use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the
expiration of the Warrants in accordance with the provisions of this Agreement. If any such registration statement has not been declared effective by the 60th Business Day following the closing of the Business Combination, holders of the Warrants
shall have the right, during the period beginning on the 61st Business Day after the closing of the Business Combination and ending upon such registration statement being declared effective by the Commission, and during any other period when the
Company shall fail to have maintained an effective registration statement covering the shares of Common Stock issuable upon exercise of the Warrants, to exercise such Warrants on a “cashless basis,” by exchanging the Warrants (in
accordance with Section 3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common
Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) over the Warrant Price by (y) the Fair Market Value. Solely for purposes of this subsection 7.4.1, “Fair Market
Value” shall 

  
 16 

 
mean the average closing price of the Common Stock for the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent
from the holder of such Warrants or its securities broker or intermediary. The date that notice of cashless exercise is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless
exercise” of a Public Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the
Warrants on a cashless basis in accordance with this subsection 7.4.1 is not required to be registered under the Securities Act and (ii) the shares of Common Stock issued upon such exercise shall be freely tradable under United States
federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act (or any successor rule)) of the Company and, accordingly, shall not be required to bear a restrictive legend. Except as provided
in subsection 7.4.2, for the avoidance of any doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three
sentences of this subsection 7.4.1. 
 7.4.2    Cashless Exercise at Company’s Option. If the Common
Stock is at the time of any exercise of a Warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act (or any successor rule), the
Company may, at its option, require holders of Public Warrants who exercise Public Warrants to exercise such Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) as
described in subsection 7.4.1 and (i) in the event the Company so elects, the Company shall not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the Common Stock
issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary or (ii) if the Company does not so elect, the Company agrees to use its best efforts to register or qualify for sale the Common Stock issuable
upon exercise of the Public Warrants under the blue sky laws of the state of residence of the exercising Public Warrant holder to the extent an exemption is not available. 

8.    Concerning the Warrant Agent and Other Matters. 

8.1    Payment of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be imposed
upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of the Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares of
Common Stock. 
 8.2    Resignation, Consolidation, or Merger of Warrant Agent. 

8.2.1    Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may
resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or
otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If 

  
 17 

 
the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the
holder of a Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of
a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having
its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor
Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if
for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such
predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such
successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations. 
 8.2.2    Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any
such appointment. 
 8.2.3    Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant
Agent may be merged or with which it may be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.

 8.3    Fees and Expenses of Warrant Agent. 

8.3.1    Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such
Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder. 

8.3.2    Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be
performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement. 

  
 18 

 8.4    Liability of Warrant Agent. 

8.4.1    Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant
Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically
prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, President, Executive Vice President, Vice President, Secretary or Chairman of the Board of the Company
and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement. 

8.4.2    Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful
misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the
execution of this Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct or bad faith. 

8.4.3    Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement
or with respect to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant.
The Warrant Agent shall not be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts
that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or
as to whether any shares of Common Stock shall, when issued, be valid and fully paid and non-assessable. 

8.5    Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees
to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the
Warrant Agent for the purchase of shares of Common Stock through the exercise of the Warrants. 
 8.6    Waiver.
The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust Account (as defined in that certain
Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the
Trust Account for any reason whatsoever. The Warrant Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account. 

  
 19 

 9.    Miscellaneous Provisions. 

9.1    Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the
Warrant Agent shall bind and inure to the benefit of their respective successors and assigns. 
 9.2    Notices.
Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by
certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows: 

Altitude Acquisition Corp. 
 400
Perimeter Center Terrace Suite 151 
 Atlantic, Georgia 30346 

Attention: Gary Teplis, President and Chief Executive Officer 

Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent
shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed
in writing by the Warrant Agent with the Company), as follows: 
 Continental Stock Transfer & Trust Company 

1 State Street, 30th Floor 
 New
York, NY 10004 
 Attention: Compliance Department 

in each case, with copies to: 
 White &
Case LLP 
 1221 Avenue of the Americas 

New York, NY 10020 
 Attn: Joel L.
Rubinstein, Esq. 
 Email: joel.rubinstein@whitecase.com 

and 
 Ellenoff Grossman & Schole LLP

 1345 Avenue of the Americas 

New York, NY 10105 
 Attn: Douglas
S. Ellenoff 
 Stuart Neuhauser 

Email: ellenoff@egsllp.com 

sneuhauser@egsllp.com 

  
 20 

 9.3    Applicable Law. The validity, interpretation, and
performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this
Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The
Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, this Section 9.3 will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. 

9.4    Persons Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer upon, or
give to, any person or corporation other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.
All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants. 

9.5    Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at
the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit such holder’s Warrant for inspection by the
Warrant Agent. 
 9.6    Counterparts. This Agreement may be executed in any number of original or facsimile
counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 

9.7    Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement
and shall not affect the interpretation thereof. 
 9.8    Amendments. This Agreement may be amended by the
parties hereto without the consent of any Registered Holder (i) for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to
matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the Registered Holders, and (ii) to provide for the delivery of Alternative
Issuance pursuant to Section 4.4. All other modifications or amendments, including any modification or amendment to increase the Warrant Price or shorten the Exercise Period shall require the vote or written consent of the Registered Holders of
50% of the number of the then outstanding Public Warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants or Working Capital Warrants or any provision of this Agreement with respect to the Private Placement
Warrants or Working Capital Warrants, 50% of the number of then outstanding Private Placement Warrants and Working Capital Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period
pursuant to Sections 3.1 and 3.2, respectively, without the consent of the Registered Holders. 

  
 21 

 9.9    Severability. This Agreement shall be deemed severable,
and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or
provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable. 

[Signature Page Follows] 

  
 22 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first above written. 
  

			
	ALTITUDE ACQUISITION CORP.

 
			
		
	By:	 	  

 
			
	Name: Gary Teplis
	Title: President and Chief Executive Officer

 
			
	
	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent

 
			
		
	By:	 	  

 
			
	Name:
	Title:

 [Signature Page to Warrant Agreement] 

 EXHIBIT A 

Form of Warrant Certificate 

[FACE] 
 Number 

Warrants 
 THIS WARRANT
SHALL BE VOID IF NOT EXERCISED PRIOR TO 
 THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR 

IN THE WARRANT AGREEMENT DESCRIBED BELOW 

ALTITUDE ACQUISITION CORP. 

Incorporated Under the Laws of the State of Delaware 

CUSIP [        ] 

Warrant Certificate 

This Warrant Certificate certifies that
                , or registered assigns, is the registered holder of warrant(s) evidenced hereby (the “Warrants” and each, a
“Warrant”) to purchase shares of Class A common stock, $0.0001 par value per share (“Class A Common Stock”), of Altitude Acquisition Corp., a
Delaware corporation (the “Company”). Each whole Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and non-assessable shares of Class A Common Stock as set forth below, at the exercise price (the “Warrant Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or
through “cashless exercise” as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Warrant Price at the office or agency of the Warrant Agent
referred to below, subject to the conditions set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement. 

Each whole Warrant is initially exercisable for one fully paid and non-assessable share of
Class A Common Stock. No fractional shares will be issued upon exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in a share of Class A Common Stock, the Company will,
upon exercise, round down to the nearest whole number the number of shares of Class A Common Stock to be issued to the Warrant holder. The number of shares of Class A Common Stock issuable upon exercise of the Warrants is subject to
adjustment upon the occurrence of certain events set forth in the Warrant Agreement. 

 The initial Warrant Price per share of Class A Common Stock for any Warrant is equal to
$11.50 per share. The Warrant Price is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement. 

Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent
not exercised by the end of such Exercise Period, such Warrants shall become void. 
 Reference is hereby made to the further provisions of
this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same effect as though fully set forth at this place. 

This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement. 

This Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York. 

 

			
	ALTITUDE ACQUISITION CORP.

 
			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 
			
	
	CONTINENTAL STOCK TRANSFER & TRUST COMPANY,
as Warrant Agent

 
			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 2 

 [Form of Warrant Certificate] 

[Reverse] 
 The Warrants
evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive shares of Class A Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of
                , 2020 (the “Warrant Agreement”), duly executed and delivered by the Company to
Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is
hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words “holders” or
“holder” meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company. Defined terms used in this
Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement. 
 Warrants may be exercised at
any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon
properly completed and executed, together with payment of the Warrant Price as specified in the Warrant Agreement (or through “cashless exercise” as provided for in the Warrant Agreement) at the principal corporate trust office of the
Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its
assignee, a new Warrant Certificate evidencing the number of Warrants not exercised. 
 Notwithstanding anything else in this Warrant
Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering the shares of Class A Common Stock to be issued upon exercise is effective under the Securities Act and
(ii) a prospectus thereunder relating to the shares of Class A Common Stock is current, except through “cashless exercise” as provided for in the Warrant Agreement. 

The Warrant Agreement provides that upon the occurrence of certain events the number of shares of Class A Common Stock issuable upon
exercise of the Warrants set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest in a share of Class A Common Stock, the
Company shall, upon exercise, round down to the nearest whole number of shares of Class A Common Stock to be issued to the holder of the Warrant. 

Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person
or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or
Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants. 

  
 3 

 Upon due presentation for registration of transfer of this Warrant Certificate at the office
of the Warrant Agent a new Warrant Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject to the limitations
provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection therewith. 
 The
Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise
hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder
hereof to any rights of a stockholder of the Company. 
 Election to Purchase 

(To Be Executed Upon Exercise of Warrant) 

The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive
             shares of Class A Common Stock and herewith tenders payment for such shares of Class A Common Stock to the order of Altitude Acquisition Corp. (the
“Company”) in the amount of $             in accordance with the terms hereof. The undersigned requests that a certificate for such shares of Class A
Common Stock be registered in the name of                 , whose address is and that such shares of Class A Common Stock be delivered to
                 whose address is                . If said number of shares
of Class A Common Stock is less than all of the shares of Class A Common Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares of Class A Common Stock be
registered in the name of                 , whose address is
                 and that such Warrant Certificate be delivered to
                , whose address is                 . 

In the event that the Warrant has been called for redemption by the Company pursuant to Section 6.1 of the Warrant
Agreement and the Company has required cashless exercise pursuant to Section 6.3 of the Warrant Agreement, the number of shares of Class A Common Stock that this Warrant is exercisable for shall be determined in
accordance with subsection 3.3.1(b) and Section 6.3 of the Warrant Agreement. 
 In the event that the
Warrant is a Private Placement Warrant or a Working Capital Warrant that is to be exercised on a “cashless” basis pursuant to subsection 3.3.1(c) of the Warrant Agreement, the number of shares of Class A Common Stock that this
Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement. 
 In the event that
the Warrant is to be exercised on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement, the number of shares of Class A Common Stock that this Warrant is exercisable for shall be determined in
accordance with Section 7.4 of the Warrant Agreement. 

  
 4 

 In the event that the Warrant may be exercised, to the extent allowed by the Warrant
Agreement, through cashless exercise (i) the number of shares of Class A Common Stock that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless
exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to
receive shares of Class A Common Stock. If said number of shares of Class A Common Stock is less than all of the shares of Class A Common Stock purchasable hereunder (after giving effect to the cashless exercise), the undersigned
requests that a new Warrant Certificate representing the remaining balance of such shares of Class A Common Stock be registered in the name of
                , whose address is                  and that such Warrant
Certificate be delivered to                 , whose address is
                . 
 [Signature Page Follows]

  
 5 

			
	Date:                 , 20        	  	  

		  	Signature
		
		  	  

		  	  

		  	  

		  	(Address)
		
		  	  

		  	(Tax Identification Number)

 Signature Guaranteed: 
  

 
 THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN
ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)). 

  
 6 

 EXHIBIT B 

PRIVATE PLACEMENT WARRANTS LEGEND 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND
MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY
ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG ALTITUDE ACQUISITION CORP. (THE “COMPANY”), ALTITUDE ACQUISITION HOLDCO LLC AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY
NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED
TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS. 

SECURITIES EVIDENCED BY THIS CERTIFICATE AND SHARES OF CLASS A COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO
REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.Exhibit 10.8

 

Pursuant
to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit
because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

Exclusive
License Agreement 

Between

The
UAB Research Foundation

and

Incysus,
Ltd. 

 

March
10, 2016

 

     

     

    

 

table
of contents

 

	 	Page
	
        Article
        1: Definitions

         
	3
	
        Article
        2: Grant of License

         
	7
	
        Article
        3: Development and Commercialization

         
	9

         

	
        Article
        4: Protection of The Licensed Patents; Patent Prosecution 

         
	10
	
        Article
        5: Financial terms

         
	11
	
        Article
        6: Recordkeeping and Audit Rights

         
	14
	
        Article
        7: Infringement; Enforcement; Other Legal Claims 

         
	15
	
        Article
        8: Other Covenants and Agreements

         
	19
	
        Article
        9: Term and Termination

         
	21
	
        Article 10: Covenants;
        Representations and Warranties; Limitations on UABRF’s Obligations

         
	22
	
        Article
        11: Liability and Indemnification

         
	23
	
        Article
        12: Miscellaneous

         
	25
	 	 
	Exhibit A: Licensed Patents 	29
	 	 
	Exhibit B:  Development and Commercialization Plan	30
	 	 
	Exhibit C: Milestones	31
	 	 
	Exhibit D: Form of Stock Purchase Agreement	33
	 	 
	Exhibit E: Form of Development & Commercialization Progress Report   	34
	 	 
	Exhibit F: Research Plan	35

 

    Page 2 of 35 

     

    

 

EXCLUSIVE LICENSE AGREEMENT

 

This exclusive license
agreement (this “Agreement”) is made and is effective as of March 10th, 2016 (the “Effective Date”)
between The UAB Research Foundation (“UABRF”), a non-profit 501(c)(3) corporation incorporated in the State of Alabama
with its principal place of operations at 701 20th Street South, Birmingham, AL 35233 and Incysus, Ltd. (the “Licensee”),
an entity incorporated in Bermuda, with its principal place of operations at Clarendon
House 2 Church Street Hamilton HM 11, Bermuda.

 

RECITALS

 

WHEREAS, UABRF owns
all right, title and interest in the intellectual property described in UABRF intellectual property disclosure number [*****] entitled
 “[*****]” which was developed by [*****] while employed by the University of Alabama at Birmingham (the “Inventors”),
and has filed for patent protection with respect to such intellectual property; and

 

WHEREAS, UABRF has
the right to grant licenses to the intellectual property and the Licensed Patents (defined below) and desires to have the same
developed and commercialized to benefit the public; and

 

WHEREAS, Licensee,
a biotechnology company created to develop cancer immunotherapy technology, desires an exclusive license to the Licensed Patents;

 

NOW, THEREFORE, in
consideration of the premises described above and the mutual promises and agreements set forth in this Agreement, the Parties agree
as set forth below.

 

Article
1

Definitions

 

The Definitions used in this Agreement
are set forth below.

 

1.1          
“Affiliate” means any Person that directly or indirectly controls, is controlled by, or is under common control
with a Party. “Control” means (i) the beneficial ownership of at least fifty percent (50%) of the voting securities
of a Person with voting equity, or (ii) the power to direct or cause the direction of the management or policies of a Person.

 

1.2          
“Agreement” means this agreement, as amended from time to time in accordance with the terms and conditions set
forth in this agreement.

 

1.3          
“Applicable Law” means all laws, statutes and regulations promulgated by all Regulatory Authorities and all
Governmental Authorities.

 

1.4           “Change
in Control” means, with respect to an entity, a transaction or series of related transactions as a result of which a
Person or group of Persons acting in concert directly or indirectly acquires control of the entity or acquires any of the
entity’s assets that are, individually or in the aggregate, material to its performance under this Agreement. The
transactions may be in any form or combination of forms, including an issuance of voting securities, a grant of one or more
proxies, the establishment of a voting agreement, a merger (whether or not the entity survives), a share exchange, or a
reorganization, a recapitalization or an asset sale.

 

    Page 3 of 35 

     

    

 

1.5          
“Development and Commercialization Plan” means development, manufacturing, marketing, and commercialization
activities proposed to be undertaken by the Licensee with respect to the Licensed Patents as set forth on attached Exhibit B.

 

1.6          
“Disclaimed Licensed Patent(s)” means any Licensed Patent in respect of which the Licensee decides not to pursue
protective rights, undertake, or be responsible for, the payment of Protection Expenses, as described in Section 4.1(e) and (f)
of this Agreement.

 

1.7          
“First Commercial Sale” means the first Sale of a Licensed Product to a Third Party.

 

1.8          
“For Value” means any consideration, remuneration or benefit of any kind, whether received directly or indirectly,
including, but not limited to, cash, equity, debt, preferential treatment, including waiver, rebate, discount, etc.

 

1.9          
“Governmental Authorities” means, with respect to each country or jurisdiction, all legislative and governmental
authorities, bodies, commissions, agencies or other instrumentalities of such country or jurisdiction.

 

 1.10         “Infringement Notice” is defined in Section 7.1 of this Agreement.

 

 1.11         “Inventors” is defined in the first recital of this Agreement.

 

1.12        
“Licensed Field of Use” means cellular therapies in humans.

 

1.13       
“Licensed Patents” means (a) the patents and/or patent applications set forth on attached Exhibit A, (b) any
U.S. and foreign patents and patent applications that directly or indirectly claim priority to such patents and patent applications,
(c) all patents proceeding from any of the foregoing, and (d) all foreign equivalents, divisionals, continuations, continuations-in-part,
reissues, reexaminations, substitutions and extensions of any patent or patent application described in (a) – (c) above.
Licensed Patents does not include any patent and/or patent application that is a Disclaimed Licensed Patent.

 

1.14        
“Licensed Product” means any product or part thereof, composition, material, process, or service, the development,
manufacture, use, import, export, offer for sale, or sale of which is covered by, or which cannot be undertaken or completed without
infringing, a Valid Patent Claim set forth in any Licensed Patent. For the avoidance of doubt, for purposes of Section 5.5, any
product or part thereof, composition, material, process, or service which would be deemed to be a Licensed Product if such product
or part thereof, composition, material, process, or service were sold in any country or jurisdiction in which a Valid Patent Claim
exists shall still be considered to be a Licensed Product with respect to sales in a country or jurisdiction in which no Valid
Patent Claim exists.

 

    Page 4 of 35 

     

    

 

 1.15         “Licensed Territory” means worldwide.

 

1.16        
“Net Sales” means the gross amount set forth on the invoice relating to any Sale of a Licensed Product, less
(a) discounts actually allowed, (b) rebates, price reductions, rebates to social and welfare systems, charge backs, government
mandated and similar rebates, (c) credits for claims, allowances, retroactive price reductions or returned goods, (d) prepaid freight
and insurance, (e) customs duties, sales taxes or other governmental charges actually paid in connection with such Sale (but excluding
income tax), transportation, or delivery (including annual fees due under Section 9008 of the United States Patient Protection
and Affordable Care Act of 2010 (Pub. L. No. 111-48); (f) outbound transportation expenses prepaid or allowed; and (g) invoiced
amounts written off as uncollectible [*****]. Where a Licensed Product is not used, transferred or exchanged For Value, the Net
Sales will be the net invoice price of products of similar kind and quality, sold or transferred For Value at similar quantities,
currently being offered by the Licensee, a Sublicensee or by other manufacturers. Where there is no comparable sale or transfer
For Value, the Net Sale will be the Licensee’s or Sublicensee’s cost of manufacture, determined by the Licensee’s
or Sublicensee’s customary accounting procedures, plus [*****]. Components of Net Sales shall be determined in the ordinary
course of business using the accrual method of accounting in accordance with generally accepted accounting practices.

 

1.17        
 “Non-Commercial Research Purposes” means any use and practice for academic research and educational purposes,
including collaboration with other non-profit entities, but expressly excluding any commercial or for-profit purposes or uses.

 

1.18        
“Non-Royalty Income” means anything received by Licensee or its Affiliates or Sublicensees For Value in consideration
of (i) the transfer of Licensed Product in a transaction or portion of a transaction that is not structured to generate royalty
payments based on Net Sales; or (ii) the grant of a right (through sublicense or otherwise) to practice the Licensed Patents and/or
to make, have made, use or sell Licensed Product in a transaction or portion of a transaction that is not structured to generate
royalty payments based on Net Sales.  For purposes of clarity, Non-Royalty Income includes upfront fees, milestone payments
and advances and any consideration received by Licensee from the purchase by a Sublicensee of shares of the Licensee in exchange
for a transaction or right as described in (i) or (ii) above. Non-Royalty Income shall not include [*****].

 

 1.19         “Parties” means UABRF and the Licensee and each of them individually is a “Party”.

 

1.20        
“Person” means an individual, corporation, partnership, trust, business trust, association or any other entity
with a separate legal identity, including the Parties.

 

 1.21         “Proprietary Information” is defined in Section 8.4 of this Agreement.

 

1.22        
“Protection Activities” means preparation of, obtaining, filing for, securing, pursuing, prosecuting, and continuing
or maintaining the patents and patent applications, including through participation in post-grant review, inter partes review,
ex parte reexamination, or opposition proceedings.

 

    Page 5 of 35 

     

    

 

1.23       
 “Protection Expenses” means all actual, out-of-pocket legal fees, costs and expenses reasonably incurred by
UABRF in the performance of the Protection Activities, such fees, costs and expenses to be documented by written invoice.

 

1.24        
“Regulatory Documents” means any document or information prepared for submission to, or submitted to any Governmental
Authority with respect to the Licensed Patents that have been provided to UABRF by UAB and/ or an Inventor. Regulatory Documents
shall include, but not be limited to, documents related to investigational new drug applications.

 

1.25        
 “Regulatory Authority” means, with respect to any particular country or jurisdiction, the Governmental Authority
with the primary responsibility for the evaluation or approval of cellular therapy products and processes before such products
and/or services can be tested, marketed, promoted, distributed or sold in such country or jurisdiction, including Governmental
Authorities that have jurisdiction over the pricing of such products. The term Regulatory Authority includes the Food and Drug
Administration of the United States.

 

1.26        
“Representative(s)” means, with respect to each Party and their Affiliates, all directors, officers, employees,
agents and advisors and with respect to UABRF only, the trustees of its Affiliate, UAB and any Third Party described in Section
8.4(d) to whom the Receiving Party provides the Proprietary Information in accordance with the conditions set forth in Section
8.4(d).

 

1.27        
“Royalty Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period from
the first sale of such Licensed Product in such country until the earlier of: (a) expiration of the last Valid Patent Claim of
a Licensed Patents covering such Licensed Product in such country; or (b) fifteen (15) years from First Commercial Sale of such
Licensed Product in such country.

 

1.28        
 “Sale or Sales” means any use, transfer or exchange, For Value, of a Licensed Product. Sales include all Sales
by the Licensee and its Affiliates and Sublicensees, and include any transfer by the Licensee to an Affiliate or Sublicensee where
there is no subsequent Sale (i.e. the Licensed Product is not further resold or transferred). For the avoidance of doubt, Sales
shall not be deemed to include (a) any transfer by the Licensee where there is a subsequent Sale of the Licensed Product; only
the subsequent Sale is used to calculate any amount due, (b) the use, performance or provision of a Licensed Product for research
and development purposes, including preclinical, clinical or translational trials or for compassionate use or as samples or (c)
reasonable distributions as samples or given as donations for indigent use. A Licensed Product shall be considered sold when the
Licensed Product is shipped or invoiced, whichever is earlier.

 

1.29        
 “Sublicensee” means a Person to whom the Licensee has granted a sublicense pursuant to Section 2.5 of this
Agreement.

 

1.30        
“Technical Information” shall mean technical information, know-how, processes, procedures, compositions, devices,
methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by one or more of the Inventors
and disclosed to UABRF by the Inventors before the Effective Date which are not covered by a Valid Patent Claim but which is/are
necessary for practicing one or more invention claimed in the Licensed Patents.

 

    Page 6 of 35 

     

    

 

1.31          “Term” is defined in Section
9.1 of this Agreement.

 

1.32         “Third Party” means any
Person other than the Parties and their Affiliates and Representatives.

 

1.33         “United States” means
the United States of America.

 

1.34         “United States Government”
means the Federal Government of the United States.

 

1.35         “Valid Patent Claim” means
(i) a pending patent claim included within the Licensed Patents or (ii) an issued and unexpired patent claim included within the
Licensed Patents which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other Governmental
Authority of competent jurisdiction, to which an appeal has not or cannot be taken within the time allowed for appeal, and which
has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.

 

Article
2

Grant
of License

 

2.1          
Grant of License. Subject to the terms and upon the conditions set forth in this Agreement, UABRF hereby grants to the Licensee
and its Affiliates an exclusive right and license to (a) practice the Licensed Patents and (b) make, have made, develop, have developed,
manufacture, have manufactured, use, have used, rent, lease, offer to sell, sell, have sold, distribute, import and export Licensed
Products, within the Licensed Field of Use in the Licensed Territory during the Term. UABRF shall transfer or provide to Licensee
a copy of all Technical Information requested by the Licensee, which has not been previously provided, within [*****] of the Effective
Date. UABRF shall transfer or provide a copy to Licensee of all Regulatory Documents (i) within [*****] of UABRF’s receipt
of such from the Inventors or (ii) within [*****] of the submission or receipt of such Regulatory Documents by UABRF, whichever
shall occur first. For the avoidance of doubt, UABRF shall promptly after the Effective Date transfer to Licensee a copy any investigational
new drug application related to any Licensed Patent.

 

2.2           Rights
of the United States Government. It is understood that a United States Governmental Authority (through an award numbered [*****])
has funded research, during the course of or under which the Licensed Patents were conceived or made. The United States Government
is entitled, as a right, under the provisions of 35 U.S.C. §§ 200-212 and applicable regulations of Chapter 37 of the
Code of Federal Regulations (“Bayh-Dole”), to a non-exclusive, non-transferable, paid-up license to practice or have
practiced and use the affected Licensed Patents for governmental purposes. The Licensee acknowledges that the rights and license
granted to it pursuant to this Agreement are subject to any and all rights of the United States Government.

 

2.3           Reservation
of Rights by UABRF and its Affiliates. UABRF reserves the right, for itself and for its Affiliates, to:

 

    Page 7 of 35 

     

    

 

		(a)	practice and use, and to permit its Representatives to practice and use, the Licensed Patents within
the Licensed Field of Use solely for Non-Commercial Research Purposes;

		(b)	grant to non-profit academic, educational or research institutions and Governmental Authorities,
non-exclusive, royalty-free licenses to practice and use the Licensed Patents within the Licensed Field of Use solely for Non-Commercial
Research Purposes;

		(c)	permit their respective Representatives to disseminate and publish scientific findings from research
related to the Licensed Patents; and

		(d)	practice, use and otherwise commercialize, including licensing, the Licensed Patents to Third Parties
for applications and uses outside of the Licensed Field of Use.

 

2.4           Title
Remains with UABRF. All right, title and interest in and to the Licensed Patents remains with UABRF. Except as provided in
this Agreement, no express or implied licenses with respect to the Licensed Patents or any other rights are transferred or granted
to the Licensee by implication, estoppel or otherwise. UABRF represents and certifies that it has the legal right to grant the
rights under this Agreement.

 

2.5           Right
to Grant Sublicenses. The Licensee has the right to grant sublicenses to any Person under this Agreement on the following terms
and conditions:

 

		(a)	the execution of a sublicense shall not in any way diminish, reduce or eliminate any of the Licensee’s
obligations under this Agreement;

		(b)	any sublicense so granted is limited to the Licensed Field of Use;

		(c)	any sublicense so granted shall be subject and subordinate to, and consistent with, the terms of
this Agreement;

		(d)	the Licensee may not [*****];

		(e)	any sublicense shall also provide that, in the event this Agreement is terminated or upon the expiration
of the Term, (i) the Licensee shall notify the Sublicensee of the termination or expiration, (ii) the sublicense will terminate
simultaneously with the termination or expiration of this Agreement, and (iii) the Sublicensee may enter into a license agreement
with UABRF on substantially the same terms as the Sublicensee’s sublicense with the Licensee with UABRF’s approval,
provided that [*****] or [*****];

		(f)	all sublicenses are to be For Value;

		(g)	the Licensee shall provide UABRF with a copy of any such sublicense granted by it under this Agreement
promptly after the execution of the sublicense;

		(h)	all such copies of sublicense agreements may be redacted to exclude confidential scientific information
and other information required by the Sublicensee to be kept confidential, provided that [*****] shall be retained and shall not
be redacted; the disclosure of sublicense agreements to UABRF shall be subject to the confidentiality obligations set forth in
this Agreement;

		(i)	UABRF is a third party beneficiary to each sublicense and each agreement evidencing a sublicensing
arrangement shall include a statement and an acknowledgement by the Sublicensee to this effect; and

 

    Page 8 of 35 

     

    

 

		(j)	Subject to the sublicensing terms in this Section 2.5, Sublicensees may be permitted, on a case-by-case
basis, to further sublicense their rights to practice the Licensed Patents.  Prior to the execution of any sublicense agreement
which allows a Sublicensee to further sublicense, Licensee shall present to UABRF a reasonably detailed business justification
for the proposed sublicense, as well as [*****], for UABRF’s review and approval.  Licensee shall proceed with execution
of the proposed sublicense agreement only with UABRF’s prior written consent, such consent shall not be unreasonably withheld.

 

Article
3

Development
and Commercialization

 

3.1           Development
and Commercialization Plan. During the Term, the Licensee shall use good faith, reasonable commercial efforts to develop,
manufacture, commercialize and market the Licensed Patents through a diligent program designed to accomplish the commercial exploitation
of the same and to make the technology covered by or embedded in the Licensed Patents available to the general public in accordance
with the procedures and practices that are usual and customary for similar technologies and industries utilizing those resources
that would be employed by the Licensee of a product or compound of similar market potential at a similar stage in its development
or product life as the Licensed Patents taking into account, without limitation, issues of safety and efficacy, product profile,
intellectual property situation, regulatory environment and other relevant scientific and commercial factors). The Parties acknowledge
that the Licensee has provided to UABRF the Development and Commercialization Plan set forth on attached Exhibit B which sets forth
its current development and commercialization objectives. The Parties further acknowledge and agree that the Development and Commercialization
Plan is, and the development and commercialization milestones, each set forth on attached Exhibits B and C, are reasonable.

 

3.2           Amendment
of Development and Commercialization Plan and Milestones. All variations and deviations from and changes to the Development
and Commercialization Plan and milestones [*****].

 

3.3           Development
and Commercialization Report. The Licensee shall provide UABRF not more than once annually written progress reports detailing
generally the activities of the Licensee, its Affiliates and all Sublicensees relating to the Development and Commercialization
Plan (Exhibit B) and if any of the Milestones on Exhibit C have been attained. Such reports are to be provided substantially in
the format shown in Exhibit E.

 

3.4           Regulatory
Approvals. With respect to each Licensed Product, and to the extent regulatory approval is required, the Licensee shall use
its reasonable efforts to obtain the approval of each applicable Regulatory Authority prior to the First Commercial Sale in each
country/jurisdiction in which the Licensee intends to sell Licensed Products.

 

3.5           Patent
Markings. If required by Applicable Law, all Licensed Products manufactured and/or sold shall be marked in such a manner as
to conform to the Applicable Law of such country/jurisdiction.

 

    Page 9 of 35 

     

    

 

3.6           Manufacturing
in the United States. The Licensee shall use its best efforts to substantially manufacture in the United States any Licensed
Products sold in the United States that incorporates any invention or intellectual property owned by UABRF and licensed to the
Licensee under this Agreement that was developed using funds provided by a United States Governmental Authority.

 

Article
4

Protection
of The Licensed Patents; Patent Prosecution 

 

4.1           Future
Protection Activities.

 

		(a)	UABRF Retains Primary Responsibility. Subject to the terms and conditions set forth
in this Agreement, UABRF shall, from the Effective Date, continue to be primarily responsible for undertaking all Protection Activities
relating to the Licensed Patents. UABRF shall select such legal counsel as it deems appropriate to assist it in this process, provided
that such counsel is reasonably acceptable to Licensee.

		(b)	Co-operation of the Licensee. The Licensee shall reasonably cooperate with
UABRF and its designated legal counsel in connection with the Protection Activities.

		(c)	Consultation with the Licensee. UABRF shall, and shall cause its designated legal
counsel to, consult with the Licensee in connection with such Protection Activities, and the Licensee shall be given reasonable
opportunity to discuss, advise and review issues with UABRF and its designated legal counsel in connection therewith.

		(d)	Foreign Protection Requested by the Licensee. The Licensee must notify UABRF in writing
identifying in which foreign countries and jurisdictions, if any, the Licensee wishes to undertake Protection Activities with respect
to any Licensed Patents. Exhibit A shall be amended accordingly to reflect these designations.

		(e)	Foreign Patent Protection Not Requested by the Licensee. UABRF may elect to undertake
Protection Activities with respect to any Licensed Patents in any country or jurisdiction not so designated by the Licensee pursuant
to Section 4.1(d) above. In such cases (i) UABRF shall be responsible for all Protection Expenses incurred in connection therewith,
and the Licensee shall not be responsible for such expenses, (ii) the Licensed Patents so affected shall no longer be deemed to
be licensed to the Licensee and shall be deemed to have been disclaimed by the Licensee (each, a “Disclaimed Licensed Patent”),
(iii) the Licensee shall forfeit and shall no longer have any rights or obligations with respect thereto and (iv) Exhibit A shall
be amended accordingly to delete the affected Licensed Patents.

		(f)	Disclaimed Licensed Patent. The Licensee may, at any time during the Term,
                                                               provide at least [*****] written notice to UABRF that it no longer wishes to be responsible for the Protection Expenses in
                                                               connection with one or more Licensed Patents. In such cases, (i) the Licensee shall continue to be responsible for all
                                                               Protection Expenses incurred in connection therewith until the expiration of such [*****] notice period and thereafter shall
                                                               not be responsible for such expenses, (ii) the Licensed Patents so affected shall no longer be deemed to be licensed to the
                                                               Licensee and shall be deemed to have been disclaimed by the Licensee (each, a “Disclaimed Licensed Patent”),
                                                               (iii) the Licensee shall forfeit and shall no longer have any rights or obligations
with respect thereto and (iv) Exhibit A shall be amended accordingly to delete the affected Licensed Patent.

 

    Page 10 of 35 

     

    

 

4.2           Information
to the Licensee. UABRF shall provide the Licensee with copies of all issued patents relating to the Licensed Patent. UABRF
shall provide copies of all patent applications and all filings, correspondence and other related documentation pertaining to prosecutorial
matters arising from the Protection Activities, including, but not limited to, all office actions, requests for examinations and
restriction requirements.

 

Article
5

Financial
Terms 

 

5.1         
License Issue Fee. Within [*****] of the Effective Date, the Licensee shall pay to UABRF a non-refundable, non-creditable
license issue fee of [*****].

 

5.2         
Future Protection Expenses. Beginning [*****] after the Effective Date, or [*****] before the filing of the non-provisional
application of a Licensed Patent, whichever is earlier and during the Term and with respect to the Licensed Patents, other than
Disclaimed Licensed Patents, the Licensee will be financially responsible for the payment of all Protection Expenses incurred after
the Effective Date. The Licensee shall pay such amounts to UABRF within [*****] of receipt of an invoice for the same from UABRF.
UABRF shall be responsible for all Protection Expenses incurred in connection with each Disclaimed Licensed Patent in countries/jurisdictions
not designated by the Licensee pursuant to Section 4.1(d) above or after the expiration of the notice period referred to in Section
4.1(f) above.

 

5.3         
Issuance of Stock in the Licensee to UABRF. On or promptly following the Effective Date, the Licensee shall issue
to UABRF shares in the Licensee initially equivalent to a two and one-half percent (2.5%) ownership interest in Licensee, prior
to raising any outside capital to fund the Licensee, which ownership interests shall be subject to the terms and conditions of
the Stock Purchase Agreement, dated of even date herewith, a copy of which is attached to this Agreement as Exhibit D. The equity
position held by UABRF shall not be diluted until the Licensee has raised at least Twenty Million Dollars ($20,000,000.00) through
one or more rounds of investment in equity securities of the Company (or debt securities of the Company that are convertible into
or exchangeable for equity securities of the Company) (the “Threshold Amount”). Thereafter, the shares held by UABRF
may be diluted only upon the same terms and conditions [*****], until completion of an initial public offering of the Licensee’s
common stock.

 

5.4          
Funding of Research Program. The Licensee hereby agrees to support a research program, as set forth in the Research
Plan attached hereto as Exhibit F, to be carried out by UABRF’s Affiliate, the University of Alabama at Birmingham. The Parties
anticipate that the Licensee’s support of such research program shall take the form of a series of sponsored research agreements
and/or clinical trial agreements, as applicable, which the University of Alabama at Birmingham and Licensee agree to negotiate
in good faith.

 

    Page 11 of 35 

     

    

 

5.5        
 Running Royalty Payments. During the Term and with respect to each country or jurisdiction within the Licensed Territory
in which a Valid Patent Claim exists, the Licensee shall pay to UABRF royalties on all Net Sales of Licensed Products as set forth
below:

 

	Entity Accomplishing Sales	Royalty Rate to UABRF
	Licensee or Licensee’s Affiliates	[*****]
	Sublicensees 	[*****]

 

These
payments shall be made on all Net Sales arising in such country/jurisdiction until the expiration of the last Valid Patent Claim
in that country/jurisdiction. With respect to each country or jurisdiction within the Licensed Territory in which no Valid
Patent Claim exists, Licensee agrees to pay to UABRF a running royalty of [*****] on all Net Sales arising in each such country/jurisdiction
during the Term of this Agreement. For the avoidance of doubt, a running royalty shall only be payable to UABRF one time upon the
Sale of any Licensed Product to an end user or consumer. All amounts owing
to UABRF under this section shall be paid on a quarterly basis, on or before the [*****] following the end of the calendar quarter
in which such amounts were earned. 

 

5.6          
Anti-Stacking Provision. If, at any time, Licensee discovers that any Licensed Product or the use thereof in the
Licensed Field of Use or the practice of any Licensed Patent infringes claims of an unexpired patent or patents other than those
in the Licensed Patents, Licensee may, if it has not already done so, negotiate with the owner of such patents for a license on
such terms as Licensee deems appropriate. Should the license with the owner of such patents require the payment of royalties or
other consideration to such owner then the royalties otherwise payable under this Agreement may be reduced by the amount payable
[*****] to the other patent owner(s), but in no event shall the royalties payable under this Agreement be reduced by more than
[*****]. To clarify, Licensee and UABRF agree that under no circumstance shall UABRF’s royalty amount under Section 5.5 be
less than (a) [*****] when the Licensee or one of its Affiliates is the entity generating Net Sales and (b) [*****] when a Sublicensee
is the entity generating Net Sales. If a combination product incorporates a product based on a patent (other than a Licensed Patent)
to which Licensee has secured rights via an agreement with the patent owner and the owner of such patent requires the payment of
royalties or other consideration to such owner, then the royalties otherwise payable under this Agreement may be reduced by the
amount payable [*****] to the other patent owner(s), but in no event shall the royalties payable under this Agreement be reduced
by more than [*****].

 

5.7          
Lump Sum Royalties on Cumulative Net Sales. The Licensee shall pay to UABRF a lump sum amount when the cumulative
Net Sales accomplished by Licensee, its Affiliates and Sublicensees reaches the amounts set forth below in any calendar year. The
table below sets out the cumulative Net Sales amounts and corresponding lump sum payments owed to UABRF:

 

	Cumulative Net Sales Amount Reached in Calendar Year	Lump Sum Due to UABRF
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

    Page 12 of 35 

     

    

 

All amounts owing to
UABRF under this section shall be paid within [*****] of the close of any calendar year in which one of the above amounts is reached
in cumulative Net Sales made by Licensee, its Affiliates and Sublicensees.

 

5.8         
Milestone Payments. During the Term, the Licensee shall pay to UABRF the development and commercialization milestone
payments set forth in Exhibit C. Each such milestone payment is in consideration of this Agreement and shall be due to UABRF without
deduction or adjustment relating to milestones payable to other Third Parties, shall be non-creditable and non-refundable and shall
be due within [*****] of achievement. The Licensee shall provide written notice to UABRF to accompany the payment identifying the
milestone that has been achieved.

 

5.9          
Non-Royalty Income. The Licensee shall pay to UABRF the amounts as laid out in the chart below on any and all Non-Royalty
Income received by it during the Term with such payments being made to UABRF on or before the [*****] of receipt by the Licensee.
All such payments shall be accompanied by a written notification of the nature and origin of the Non-Royalty Income upon which
the payment is based, the identity of the source of such Non-Royalty Income and, if such Non-Royalty Income was received by the
Licensee or generated in a foreign currency, the rate of currency conversion and the date such conversion was calculated as described
in Section 5.13 of this Agreement. In the event that the Licensee receives Non-Royalty Income that is not cash or a cash equivalent,
the percentage of non-cash payments shall be calculated as a percentage of the then current fair market value of such non-cash
consideration. For purposes of clarity and by example only, consideration received by the Licensee in a transaction in which [*****]
or in which [*****] would not be considered Non-Royalty Income. Further, [*****] shall mean [*****] and Licensee resolves all queries
or requests for clarification made by Licensee to sites participating in the trial. The term [*****] as used below shall be as
defined in Exhibit C.

 

	YEAR 	
        PARTICIPATION PCT. IN

        NON-ROYALTY INCOME

	Effective Date until Completion of Phase I Trial (γδ T -TMZr)	25%
	From Completion of Phase I Trial to Completion of Phase II Trial (γδ T -TMZr)	10%
	From Completion of Phase II Trial and for the Remainder of the Term of this Agreement	2.5%

 

5.10       
Royalty Reports. During the term of this Agreement, Licensee shall provide UABRF written reports semiannually until
the first Sale of a Licensed Product and quarterly thereafter showing:

		i.	the occurrence of any event triggering a Milestone Payment obligation or any other payment in accordance with Section 5.8 above;
and

		ii.	a summary of all reports provided to LICENSEE by LICENSEE'S Sublicensees, including the names and addresses of all Sublicensees;
and

		iii.	the amount of any consideration received by LICENSEE from Sublicensees and an explanation of the contractual obligation satisfied
by such consideration;

		iv.	within a given fiscal quarter, the gross selling price and the number of units of all Licensed Products (identified by product
number/name) Sold in each country of the Licensed Territory, together with the calculations of Net Sales; and

		v.	within a given fiscal quarter, the royalties payable in U.S. Dollars which accrued hereunder; and

		vi.	within a given fiscal quarter, the exchange rates, if any, used in determining the amount due.

 

    Page 13 of 35 

     

    

 

5.11       
Address for Payments. Except as otherwise directed by UABRF, all amounts due to be paid by the Licensee to UABRF
pursuant to this Agreement shall be paid to UABRF at the address set forth below its signature on the signature page of this Agreement.

 

5.12       
Late Payment Penalty. The balance of any amount which remains unpaid more than [*****] after it is due to UABRF may
be assessed interest until paid at the rate equal to the lesser of [*****] or the maximum amount allowed under Applicable Law.
However, in no event shall this interest provision be construed as a grant of permission for payment delays.

 

5.13        
Currency Conversion. All amounts due to be paid to UABRF pursuant to this Agreement shall be made in United States
dollars. Any and all amounts received by the Licensee or generated in foreign currency shall be converted into United States dollars
at the official rate of exchange from such currency to United States dollars at the rate quoted in the Wall Street Journal (United
States edition) for the daily average over the calendar quarter in which running royalties are due and payable to UABRF or on a
business day no earlier than five (5) business days before payment is made to UABRF.

 

5.14       
Taxes. UABRF is exempt from paying income taxes under United States law; therefore, all payments made by Licensee
under this Agreement shall be made without deduction for taxes, assessments or other charges of any kind that are typically imposed
by United States Governmental Authority. Any tax required to be withheld by the Licensee under the laws of any foreign
country or jurisdiction for the account of UABRF shall be promptly paid by the Licensee for and on behalf of UABRF to the appropriate
Governmental Authority, and the Licensee shall use reasonable commercial efforts to furnish UABRF with proof of payment of such
tax, together with official or other appropriate evidence issued by the applicable Governmental Authority. Any such amounts actually
paid on UABRF’s behalf shall be deducted from any amounts due to be paid to UABRF under this Agreement.

 

5.15        
No Refund/Offset. Except as otherwise expressly provided under this Agreement, no amounts payable to UABRF under
this Agreement are refundable or may be offset, including any amounts paid prior to or during the period of a Patent Challenge
under Section 7.7, even if the Patent Challenge is successful or it is otherwise determined that the Licensed Patents are invalid
or unenforceable.

 

Article
6

Recordkeeping

 

6.1          
Books and Records. The Licensee shall keep complete and accurate books, accounts and other records and documentation
necessary to ascertain all transactions and events pursuant to which payments due to UABRF pursuant to this Agreement arise and
are accrued and to verify the accuracy and completeness of such amounts. All such books, accounts and other records and documentation
shall be kept at the Licensee’s principal place of business for a period of not less than [*****] following the end of the
calendar year to which they pertain.

 

    Page 14 of 35 

     

    

 

6.2          
Right to Audit. For the Term, UABRF shall have the right to have the Licensee’s books and records audited by
a qualified, independent accounting firm of its choosing, under appropriate confidentiality provisions such as those set forth
in Section 8.4 of this Agreement, to ascertain the accuracy of the reports and payments due to UABRF under this Agreement and compliance
by the Licensee, its Affiliates and its Sublicensees with their obligations pursuant to this Agreement and any sublicense. Such
audit shall be conducted upon reasonable advance notice, during normal business hours and in a manner that does not interfere unreasonably
with the Licensee’s business but not more than once in any [*****] period. If any such examination reveals that the Licensee
has underpaid or underreported any amount due under this Agreement to UABRF for any calendar quarter examined, the Licensee shall
promptly pay to UABRF the amount so underpaid or underreported.

 

6.3         
Reimbursement of Cost of Audit. If any such examination reveals that the Licensee has underpaid or underreported
any amount due under this Agreement to UABRF by more than [*****] for any calendar quarter examined, the Licensee shall immediately
reimburse UABRF the full costs and expenses incurred by it with respect to the audit.

 

Article
7

Infringement;
Enforcement; Other Legal Claims

 

7.1          
Notification of Infringement and Other Potential Claims. During the Term, each Party shall provide prompt written
notice to the other Party of any actual infringement or suspected/potential infringement of the Licensed Patents in the Licensed
Territory of which such Party is or becomes aware and shall provide, to the extent reasonable and practicable, any available evidence
of such infringement by a Third Party (an “Infringement Notice”). In addition, during the Term, the Licensee shall
also provide prompt written notice to UABRF of any facts, circumstances or events which negatively impact or which the Licensee
reasonably believes negatively impact the ability of the Licensee or its Affiliates or Sublicensees to exercise their rights or
to perform their obligations under this Agreement or any sublicense granted under this Agreement or which negatively impact UABRF’s
intellectual property rights in the Licensed Patents, and the Licensee shall provide, to the extent reasonable and practicable,
details of (i) the potential claim(s) or cause(s) of action which the Licensee reasonably believes it has or which may be asserted
by the Licensee against a Third Party and any actual claims or causes of action asserted by any Third Party against the Licensee
or the potential claim(s) or cause(s) of action the Licensee reasonably believes a Third Party may assert against the Licensee,
and (ii) sufficient information to enable UABRF to evaluate the issues and the potential effect and impact such claims may have
on its rights under this Agreement and the Licensed Patents (a “Potential Claim Notice”).

 

7.2           Licensee
Right to Pursue/Prosecute. During the Term, the Licensee shall have the right to (i) resolve, in the Licensed Field of
Use and in the Licensed Territory, any suspected/potential infringement and prosecute any infringement of any Licensed
Patents, and/or (ii) resolve any actual or potential claim or cause of action the Licensee believes it has or may have or
which a Third Party has or may have against the Licensee which negatively impact or which the Licensee reasonably believes
negatively impact the ability of the Licensee or its Affiliates or Sublicensees to exercise their rights or to perform their
obligations under this Agreement or any sublicense granted under this Agreement, in its own name and at its own expense,
provided:

 

    Page 15 of 35 

     

    

 

		(a)	the affected Licensed Patents remain exclusively licensed to the Licensee and are not a Disclaimed
Licensed Patent;

		(b)	the claim relates to a Valid Patent Claim; and

		(c)	the Licensee remains in compliance in all material respects with its obligations under this Agreement.

 

The Licensee shall use its best efforts
to abate or terminate such infringement or resolve any other actual or potential claim(s) or cause(s) of action without resorting
to litigation, which may include negotiating and executing a sublicense agreement that complies with the terms of Section 2.5 of
this Agreement. Before the Licensee commences an action with respect to any infringement or potential infringement or commences
an action filed by, or responds to an allegation raised by, a Third Party, it shall give careful consideration to the views of
UABRF and the potential effects on the public interest in making its decision whether or not to sue or how to respond. UABRF shall
use reasonable efforts to cooperate with the Licensee in connection with any remedial action undertaken by the Licensee and shall
be responsible for the costs and expenses incurred by it and for those costs and expenses incurred by it at the reasonable request
of the Licensee with respect to such cooperation.

 

		7.3	Control of Suit; Joinder; Expenses.

 

		(a)	Initiated by the Licensee. If the Licensee wishes to commence a lawsuit, it must do so within
[*****] following the date of the relevant Infringement Notice and/or Potential Claim Notice, and it shall bear all costs and expenses
incurred by it in connection with such lawsuit. UABRF shall cooperate fully with the Licensee in connection with such lawsuit and
shall be responsible for the costs and expenses incurred by it and for those costs and expenses incurred by it at the reasonable
request of the Licensee with respect to such cooperation.

 

		(b)	Initiated by UABRF. If the Licensee elects not to exercise its right to commence, or fails
to commence, an action within [*****] of the date of the relevant Infringement Notice and/or Potential Claim Notice, UABRF may
do so at its own expense, and shall retain sole control over the direction of such lawsuit. The Licensee shall cooperate fully
with UABRF in connection with such lawsuit and shall be responsible for the costs and expenses incurred by it with respect to such
cooperation. If UABRF files an infringement or other lawsuit, the Licensee may not thereafter commence a lawsuit against the same
infringing or other party with respect to the same acts of infringement or facts or circumstances which are the subject of UABRF’s
lawsuit or with respect to which settlement is reached by the infringing or other party and UABRF.

 

		(c)	Joinder by UABRF. UABRF, to the extent permitted by Applicable Law, may elect to join in
as a party to any lawsuit relating to the Licensed Patents, UABRF’s intellectual property rights in the Licensed Patents
and/or the Licensee’s ability to exercise its rights or perform
its obligations under this Agreement initiated by the Licensee, in which case, both Parties shall jointly control the lawsuit and
shall equally share the responsibility of all legal fees, costs and expenses, unless otherwise agreed to by the Parties. The Licensee
may not join UABRF in as a party to any lawsuit initiated by it without the prior written consent of UABRF, which such consent
shall not be unreasonably withheld, and without prior written agreement between the Parties as to the responsibility between the
Parties for all costs and expenses incurred by the Parties. If UABRF is involuntarily joined as a party to a lawsuit initiated
by the Licensee, the Licensee shall pay all legal fees, costs and expenses incurred by UABRF arising out of such joinder and participation,
including, but not limited to legal fees, costs and expenses reasonably incurred by legal counsel selected and retained by UABRF
to represent it in such lawsuit. While UABRF remains a party to any lawsuit initiated by the Licensee, UABRF may not thereafter
commence a lawsuit against the same Third Party with respect to the same acts or omissions which are the subject of the Licensee’s
lawsuit or with respect to which settlement is reached by the Third Party, the Licensee and UABRF.

 

    Page 16 of 35 

     

    

 

7.4          
Settlement. The Licensee may not settle or enter into a consent judgment or other voluntary final disposition of
any lawsuit relating to the Licensed Patents, UABRF’s intellectual property rights in the Licensed Patents and/or the Licensee’s
ability to exercise its rights or perform its obligations under this Agreement initiated by it or to which it is a party without
the prior written consent of UABRF, which consent shall not be unreasonably withheld. Neither Party may settle or otherwise dispose
of any lawsuit to which it is a party, which admits liability on the part of the other Party or which requires the other Party
to pay money damages or issue a formal statement without such other Party’s prior written consent.

 

7.5          
Recoveries.

 

		(a)	Lawsuit initiated by the Licensee and in which only the Licensee is a party. With respect
to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which UABRF is not a party, any recovery of damages
shall first be applied in satisfaction of the costs and expenses incurred by the Licensee in bringing such lawsuit, including attorneys’
fees, provided they are reasonably incurred, and any balance shall be treated in accordance with Section 5.5 (Running Royalty Payments).

 

		(b)	Lawsuit initiated by the Licensee and in which UABRF joins.

 

		(i)	With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which
UABRF is involuntarily joined as a party, any recovery of damages (whether compensatory or punitive in nature) shall first be applied,
pro rata, in satisfaction of the costs and expenses incurred by UABRF arising out of such joinder and participation, including,
but not limited to legal fees and expenses reasonably incurred by legal counsel selected and retained by UABRF to represent it
in such lawsuit, then in satisfaction of the costs and
expenses incurred by the Licensee in bringing such lawsuit, including attorneys’ fees, provided they are reasonably incurred.
Any balance remaining after payment of such costs and expenses, in the case of patent infringement lawsuits, shall be treated in
accordance with Section 5.5 of this Agreement as it pertains to Sales by Licensee.

 

    Page 17 of 35 

     

    

 

		(ii)	With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which
UABRF voluntarily joins as a party, any recovery of damages (whether compensatory or punitive in nature) shall first be applied
in satisfaction of the costs and expenses incurred by the Parties in bringing such lawsuit, including attorneys’ fees, provided
they are reasonably incurred and shall be applied equally or, in the case of a different agreement between the Parties, in the
same manner as the Parties have agreed to be responsible for the costs and expenses. Any balance remaining after payment of such
expenses shall be treated in accordance with Section 5.5 of this Agreement as it pertains to Sales by Licensee.

 

		(c)	Lawsuit initiated by UABRF. With respect to any lawsuit commenced by UABRF pursuant to Section
7.3(b) above, all recoveries of damages shall belong to UABRF. Furthermore, the Licensee shall pay over to UABRF any payments (whether
or not designated as “royalties”) made by an alleged infringer to the Licensee under any existing or future sublicense
authorizing Licensed Products, up to the amount of UABRF’s unreimbursed litigation expenses (including, but not limited to,
attorneys’ fees reasonably incurred).

 

7.6           Inapplicability
of Licensee’s Rights. Notwithstanding Sections 7.1 – 7.5 above, the rights and obligations of the Licensee under
this article shall not apply to (a) any Licensed Patents in which there are no Valid Patent Claims remaining or (b) any Disclaimed
Licensed Patent.

 

7.7           Patent
Challenges. In the event the Licensee, any of its Affiliates, any Sublicensee or any Third Party at the written urging of any
of these parties intends to challenge the validity or enforceability of any of the Licensed Patents in any manner, including instituting
opposition, declaratory judgment, interference, post-grant review, inter partes review, or re-examination proceeding (a “Patent
Challenge”), the Licensee shall give UABRF at least [*****] prior written notice, which shall include stating the basis for
such Patent Challenge and providing a copy of all relevant prior art or other materials used as the basis for such Patent Challenge.
In the event of a Patent Challenge, Licensee shall: [*****]. In the event of an Unsuccessful Patent Challenge, [*****]. As used
herein, “Unsuccessful” means that, upon the conclusion of the action before the court or other Governmental Authority
in which the Patent Challenge was brought, [*****]. The Licensee represents that it has reviewed the Licensed Patents and as of
the Effective Date is unaware of any reasons why issued patents would not be valid or enforceable or why pending applications would
not be valid or enforceable upon issuance.

 

    Page 18 of 35 

     

    

 

Article
8

Other
Covenants and Agreements

 

8.1           Use
of Names. No Party may, without the prior written consent of the other Party: use (a) the name of the other Party or its Affiliates,
if applicable, (b) the name or image of any Representative of the other Party, or (c) any trade-name, trademark, trade device,
service mark, or symbol owned by the other Party in any publication, marketing or advertising documentation or material; or represent,
either directly or indirectly, that any product or service of the other Party is a product or service of the representing Party
or that it is made in accordance with or utilizes the information or documents of the other Party. Notwithstanding the foregoing,
the Licensee may disclose that it has received a license from UABRF in connection with any Licensed Product, and either Party may
use the name of the other Party to the extent such use is reasonably necessary for complying with Applicable Law.

 

8.2           Publications.
In furtherance of Section 2.3(c) of this Agreement, UABRF or its Affiliates shall submit a copy of any proposed publication or
disclosure containing Proprietary Information to the Licensee at least [*****] prior to submission or disclosure. The Licensee
shall have [*****] days from its receipt to provide written notice to UABRF or its disclosing Affiliate as to (i) specific edits
to remove Licensee’s Proprietary Information prior to publication or disclosure or (ii) the need to delay such publication
or disclosure for a reasonable period of time to undertake Protection Activities. If the Licensee does not provide written notice
of such request to UABRF or its Affiliate within [*****], UABRF or its Affiliate shall be free to publish or disclose to third
parties the proposed publication or disclosure without further obligation to the Licensee.

 

8.3           Insurance
Coverage. Prior to commencing any clinical trial and during the Term, the Licensee shall cause to be in effect through purchase
from a reputable insurance company or, upon the consent of UABRF, through a self-insurance program, at its sole expense, "occurrence
based type" liability insurance coverage or, if the Licensee is unable to obtain “occurrence based type” liability
insurance, a “claims made type” liability insurance coverage (with at least [*****] tail coverage). Such insurance
coverage shall include a contractual endorsement providing coverage for all liability which may be incurred in connection with
this Agreement, including, but not limited to general liability and products liability, and such other type of insurance coverage
required by Applicable Law or which it deems necessary to enable the Licensee to perform its obligations under this Agreement.
All such insurance coverage shall list UABRF and its Affiliates as additional insureds. The Licensee shall provide evidence of
such insurance coverage to UABRF within [*****] of commencing any clinical trial and at least annually thereafter. All such insurance
coverage shall require the insurance provider, or in the case of a self-insurance program, the Licensee, to provide UABRF with
at least [*****] prior written notice of any change in the terms or cancellation of coverage.

 

8.4           Confidentiality.

 

		(a)	Exchange of Proprietary Information. The Parties acknowledge that during the Term
they are likely to share information with each other that they each consider to be confidential and proprietary (“Proprietary
Information”). For the purposes of this Agreement, the Party that discloses Proprietary Information shall be referred to
as the “Disclosing Party”
and the Party receiving the Proprietary Information, the “Receiving Party.”

 

    Page 19 of 35 

     

    

 

		(b)	Nature of Proprietary Information. The Parties agree that information provided to
the other Party shall be deemed to be Proprietary Information if it can reasonably be considered to be proprietary, non-public
information. Any information that is disclosed orally and that could not reasonably be considered to be proprietary and non-public
information will only be deemed to be Proprietary Information if it is , summarized and reduced to writing and identified as “Proprietary”
or “Confidential” in writing to the other Party within [*****] of such disclosure. Notwithstanding the above, the Parties
specifically agree that any reports provided by the Licensee pursuant to this Agreement shall be considered Proprietary Information.

 

		(c)	Restrictions. With respect to all Proprietary Information disclosed to it, the Receiving
Party (i) shall keep it confidential (other than as permitted by this Agreement), (ii) shall store and maintain it with the same
diligence and care as its own proprietary information, but no less than reasonable diligence and care, (iii) may only use it for
the purpose for which it was disclosed by the Disclosing Party, (iv) may not disclose it (other than to Affiliates, Sublicensees
or as permitted by this Agreement), unless such Third Party is contractually bound by confidentiality restrictions at least as
stringent as those contained herein; (v) may not deconstruct, modify or copy it (other than as permitted by this Agreement), and
(vi) may not transfer or assign it to any Third Party (other than as permitted by this Agreement)without the prior written consent
of the Disclosing Party.

 

		(d)	Access to the Proprietary Information. The Proprietary Information may be used by,
and disclosed to, on an “as-needed” basis, the Receiving Party’s Representatives. The Licensee may disclose Proprietary
Information relating to the Licensed Patents to investors, prospective investors, consultants, collaborators and other Third Parties
in the chain of manufacturing and distribution, if and only if, the Licensee obtains from such recipient a written confidentiality
agreement, the provisions of which are at least as protective of UABRF’s Proprietary Information as these set forth in this
section 8.4. Each Party will promptly notify the other Party of any unauthorized use of or access to the Proprietary Information
of which it becomes aware.

 

		(e)	Exceptions to Confidentiality Obligation. The restrictions of confidentiality described
above shall not apply to Proprietary Information (i) which as of the Effective Date or subsequent thereto is or becomes available
to the public without breach of this Agreement, (ii) if it is lawfully obtained from a Third Party not bound by similar confidentiality
and use restrictions and obligations, (iii) if it is known by the Receiving Party prior to disclosure as evidenced by contemporaneous
records, or (iv) if it is at any time developed by the Receiving Party independently of any disclosure made pursuant to this Agreement.
In addition, the confidentiality obligations shall not apply to the Receiving Party if the Receiving Party is legally required
by applicable law, court order or Governmental Authority to disclose the Information, provided the Receiving Party discloses only
the minimum to comply and, if possible and in light of
the circumstances, provides reasonable prior notice to the Disclosing Party to enable it to contest the requirement or to seek
a protective order.

 

    Page 20 of 35 

     

    

 

		(f)	Termination or Expiration of this Agreement. Upon the expiration of the Term, or the earlier
termination of this Agreement, each Receiving Party shall, at the Disclosing Party’s option and upon written notice thereof
to the Receiving Party, return all Proprietary Information, copies and other tangible expressions thereof, to the Disclosing Party
or provide the Disclosing Party with written notice that the Proprietary Information in its possession, or in the possession of
its Representatives, has been destroyed within [*****] after receipt of the Disclosing Party’s written notice to the Receiving
Party requiring the Receiving Party to destroy the Proprietary Information in its possession. The Receiving Party may retain one
archival copy of the Information for purposes of compliance of its obligations under this Agreement.

 

		(g)	Continuing Obligations after Termination/Expiration. The restrictions and obligations
set forth in Section 8.4(c) above shall continue for [*****] from the termination or expiration of this Agreement.

 

Article
9

Term
and Termination

 

9.1           Term.
This Agreement shall commence on the Effective Date and shall continue, unless terminated sooner in accordance with the terms of
this Agreement, until the date of expiration of the last to expire of any Valid Patent Claim (inclusive of any extensions, supplementary
protection certificates or their equivalents) within the Licensed Patents (the “Term”).

 

9.2           Termination
by the Licensee. The Licensee may terminate this Agreement at any time, in its sole discretion, by giving not less than [*****]
prior written notice to UABRF. Upon the reasonable request of UABRF, the Licensee shall provide assistance, at its expense, to
UABRF to enable UABRF to facilitate and effect the transfer of applicable information and documents regarding the Licensed Patents
to a new licensee.

 

9.3           Termination
by UABRF. UABRF shall have the right to immediately terminate this Agreement upon the occurrence of any one or more of the
following events:

 

		(a)	if the Licensee is in material default of any provision of this Agreement or its obligations under
this Agreement and such default has not been remedied within [*****] after receipt of a notice to cure from UABRF;

		(b)	if the Licensee fails to make a payment due under this Agreement and fails to cure such non-payment
within [*****] of receipt of a non-payment notice from UABRF;

		(c)	if the Licensee fails to diligently undertake development and commercialization activities as set
forth in the Development and Commercialization Plan, provided however, Licensee shall be deemed to have demonstrated sufficient
diligence through [*****] or [*****], and [*****] in accordance with [*****];

 

    Page 21 of 35 

     

    

 

 

		(d)	if an examination by UABRF pursuant to Section 6.2 shows an underreporting or underpayment by the
Licensee in excess of [*****] of any amounts due to UABRF under this Agreement in any [*****] period, provided however, any disputed
reporting or payment obligations by Licensee shall not be considered a breach of this provision;

		(e)	if the Licensee, any of its Affiliates, any Sublicensee, or any Third Party at the written urging
of any of these parties brings a Patent Challenge under Section 7.7 of this Agreement;

		(f)	if the Licensee, any of its Affiliates, any Sublicensee, or any Third Party at the written urging
of any of these parties issues a press release, public announcement, or news release alleging invalidity or unenforceability of
any Licensed Patent; or

		(g)	if the Licensee shall become insolvent, shall make an assignment for the benefit of its creditors,
or shall have a petition in bankruptcy filed for or against it.

 

9.4       Effect
of Termination or Expiration. Any termination or expiration of this Agreement will not relieve either Party of any obligation
or liability accrued by Licensee, its Affiliates or Sublicensee prior to such termination or expiration.

 

Article
10

Covenants;
Representations and Warranties; 

Limitations
on UABRF’s Obligations

 

10.1       Both
Parties. Each Party represents and warrants to the other Party that it is duly incorporated, validly existing and in good standing
under the laws of the jurisdiction in which it was formed, it has all necessary corporate power and authority to enter into this
Agreement and to consummate the transactions contemplated hereby, that the execution, delivery and performance of this Agreement
by it will not conflict with or result in a breach of, or entitle any party thereto to terminate, an agreement or instrument to
which it is a party, or by which any of its assets or properties are bound, and that this Agreement has been duly authorized, executed
and delivered by it and constitutes a legal, valid and binding agreement of such Party, enforceable against it in accordance with
its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization or other similar
laws affecting creditors’ rights generally.

 

		10.2	The Licensee. The Licensee makes the following representations and warranties to UABRF.

 

		(a)	The Licensee possesses the necessary expertise and skill in the technical areas pertaining to the
Licensed Patents, and to make its own evaluation of the capabilities, safety, utility and commercial application of the Licensed
Patents.

		(b)	Any activity undertaken with the Licensed Patents and the Licensed Products will be conducted in
compliance with all Applicable Laws.

 

		10.3	UABRF. UABRF makes the following representations and warranties to the Licensee.

 

		(a)	UABRF has the right to grant the license under this Agreement and, to the best of its knowledge,
has provided, or will provide, Licensee with all Technical Information and Regulatory Documents
as provided to UABRF by The University of Alabama at Birmingham and/or the Inventors.

 

    Page 22 of 35

     

    

 

		(b)	To UABRF’s best knowledge and based upon information and representations and warranties made
to it by the Inventors, UABRF has no knowledge of any defects to the title and interest in the Licensed Patents and there have
been no claims made against UABRF asserting the invalidity or non-enforceability, and with respect to the Licensed Patents, UABRF
is not aware that any such claims exist.

		(c)	The performance of Management Activities with respect to Disclaimed Licensed Patents will not conflict
with or result in a breach of any of the terms, conditions, or provisions of, or constitute a default under, this Agreement, and
no Third Party shall have any right of claim against the Licensee, with respect to this Agreement or any rights remaining therein.

 

10.3       Limitations
on UABRF’s Representations and Warranties. Except as set forth in this Agreement, UABRF makes no other representations
or warranties of any kind. In particular, UABRF makes no express or implied warranties regarding merchantability, fitness for a
particular purpose, non-infringement of the intellectual property rights of third parties, validity and scope of any Licensed Patents,
the capability, safety, efficacy, utility or commercial application or usefulness for any purpose of any Licensed Patents, or that
UABRF will not grant licenses to one or more Third Parties to make, use or sell products or perform processes that may be similar
to and/or compete with any Licensed Product.

 

10.4       Limitations
on Licensee’s Representations and Warranties. LICENSEE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, REGARDING THE RESULTS OF ITS EFFORTS TO DEVELOP, MANUFACTURE OR COMMERCIALIZE ANY LICENSED PRODUCTS.

 

10.5       No
Obligation of UABRF. Unless otherwise agreed in a writing signed by both Parties, UABRF has no obligation to:

 

		(a)	supervise, monitor, review or otherwise assume responsibility for the production, manufacture,
testing, marketing, sale or disposition of any Licensed Product;

		(b)	furnish any know-how or other information relating to the Licensed Patents, other than as specifically
provided in this Agreement; or

		(c)	bring or prosecute legal action against any Person for infringement of the Licensed Patents or
to defend a Patent Challenge.

 

Article
11

Liability
and Indemnification

 

11.1       No
Indirect, Special or Consequential Liability. None of the Parties shall under any circumstances be liable to any other Party
or any other Party’s Affiliates for indirect, incidental, special or consequential damages (including, but not limited to,
loss of production time, profits, revenue or business) resulting from or in any way related to this Agreement.

 

    Page 23 of 35

     

    

 

11.2       No
Liability of UABRF. Neither UABRF nor any of its Representatives have any liability whatsoever to the Licensee, its
Affiliates or any Sublicensee or any Person for or on account of any injury, loss or damage of any kind or nature, sustained
by, assessed or asserted against, or any other liability incurred by or imposed upon the Licensee, its Affiliates or any
Sublicensee or any Person, arising out of or in connection with or resulting from:

 

		(a)	the use of the Licensed Patents during the Term;

		(b)	the production, use, practice, lease, or sale of any Licensed Product;

		(c)	any advertising or other promotional activities with respect to (a) and/or (b) above;

		(d)	the Licensee’s compliance with, and performance of the Licensee’s representations and
warranties given under, and the Licensee’s obligations pursuant to, this Agreement; or

		(e)	any fraudulent act on the part of one or more of the Inventors that affects the title of the Licensed
Patents.

 

In addition, UABRF’s liability shall
be [*****].

 

Notwithstanding the foregoing, UABRF shall
be responsible and liable for any injury, loss or damage of any kind or nature, sustained by, assessed or asserted against, or
any other liability incurred by or imposed upon the Licensee, any Sublicensee, any of their respective Representatives or any Person,
arising out of or in connection with or resulting from (i) UABRF’s or any of its Representatives’ negligent acts or
omissions, willful malfeasance, or intentional misconduct; (ii) the practice by UABRF of the Licensed Patents prior the Effective
Date; or (iii) any breach of Applicable Law by UABRF or any of its Representatives which is the direct and sole cause of the injury,
loss or damage sustained.

 

11.3       Indemnification
by the Licensee. The Licensee agrees to indemnify and hold UABRF, its Affiliates and their respective Representatives harmless
from and against any and all claims, demands, losses, costs, expenses, deficiencies, liabilities or causes of action of any kind
or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) directly relating
to:

 

		(a)	the use of the Licensed Patents during the Term;

		(b)	the production, use, practice, lease, or sale of any Licensed Product during the Term;

		(c)	any advertising or other promotional activities with respect to (a) and/or (b) above; or

		(d)	the Licensee’s compliance with, and performance of the Licensee’s representations and
warranties given under, and the Licensee’s obligations pursuant to, this Agreement.

 

11.3       Indemnification by
UABRF. UABRF shall indemnify, defend and hold harmless Licensee, its Sublicensees, and each of their Representatives
from and against any and all claims, demands, losses, costs, expenses, deficiencies, liabilities or causes of action of any
kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense)
directly resulting from i) UABRF’s or any of its Representative’s negligence, willful malfeasance, intentional
misconduct, omission or material breach of any term of this Agreement; and ii) UABRF’s practice of the Licensed Patents
prior to the Effective Date;; and iii) UABRF’s compliance with, and performance of UABRF’s representations and
warranties given under, and UABRF’s obligations pursuant to, this Agreement.

 

    Page 24 of 35

     

    

 

Article
12

Miscellaneous

 

12.1       Entire
Agreement. This Agreement is the sole and entire agreement by and between the Parties regarding the subject matter set forth
in this Agreement, and supersedes all prior agreements. All previous negotiations, statements and preliminary instruments by the
Parties with respect to the subject matter hereof are merged in this Agreement.

 

12.2       No
Inducement. No Party has been induced, persuaded or motivated by any promise or representation made by the other Party to enter
into this Agreement.

 

12.3       Independent
Contractors. The Parties are independent contractors. No Party has the authority to bind or act on behalf of the other Party.
The Parties do not intend to create an employer/employee relationship.

 

12.4       No
Third Party Beneficiaries. This Agreement is for the exclusive benefit of the Parties and their successors and permitted assignees.
No other Person shall have any rights under this Agreement, unless and only to the extent permitted by Applicable Law.

 

12.5       Assignment.
The Licensee shall not sell, assign, transfer or otherwise dispose of this Agreement including by operation of law to a Third Party
without the prior written consent of UABRF, which consent shall not be unreasonably withheld, except that Licensee shall be permitted
to assign this Agreement in the case of: (i) an assignment to a wholly owned Affiliate of Licensee, (ii) the sale of substantially
all of the stock or assets of Licensee, or (iii) any merger or acquisition or business combination resulting in a change of control
of Licensee, provided that any assignee (a) shall have the knowledge, expertise and experience to perform this Agreement and (b)
shall ratify this Agreement and abide by all of its terms and conditions provisions. Any attempted assignment of this Agreement
not in compliance with the terms of this subsection will be null and void. No assignment will relieve any Party of the performance
of any accrued obligation that such Party may then have pursuant to this Agreement.

 

12.6       Amendments.
Any and all modifications to this Agreement shall only be effective and binding if in writing and signed by a duly authorized representative
of each Party.

 

12.7       Notices.
Any notice, request, approval or consent required to be given under this Agreement will be sufficiently given if in writing and
delivered to a Party in person, by recognized overnight courier or mailed in such Party’s national postal service, postage
prepaid to the address appearing below such Party’s signature on the last page of this Agreement, or at such other address
as each Party so designates in accordance with these criteria. Notice shall be deemed effective upon receipt if delivered in person
or by overnight courier or five (5) business days after mailing with the Party’s national postal service.

 

    Page 25 of 35

     

    

 

12.8       Disputes.

 

		(a)	Equitable Relief. Either Party may seek temporary equitable and injunctive relief in a court
of competent jurisdiction in the event of a breach or threatened breach by the other Party of its obligations under this Agreement,
without the requirement to post a bond.

 

		(b)	Internal Resolution. In the event of any dispute arising out of or relating to this
Agreement or to a breach thereof, including its interpretation, performance or termination, the Parties shall try to settle such
conflicts amicably between themselves.

 

		(c)	Mediation. In the event the Parties are still unable to resolve the dispute, the dispute
or conflict may then be submitted by a Party to a mediator, mutually agreed to by the Parties, for nonbinding mediation. The Parties
shall cooperate with the mediator in an effort to resolve such dispute.

 

		(d)	Arbitration. If the dispute is not resolved within [*****] days of its submission to the
mediator, either Party may submit the dispute for binding arbitration. The arbitration shall be conducted by one (1) arbitrator,
to be appointed by mutual agreement of the Parties. The arbitration shall be conducted in accordance with the rules and organization
agreed to by the Parties at the time or if no agreement can be reached, by the commercial rules of the American Arbitration Association,
which shall administer the arbitration. The arbitration, including the rendering of the award, shall take place in [*****] and
shall be the exclusive forum for resolving such dispute. The decision of the arbitrator shall be final and binding upon the Parties
and the expense of the arbitration, including, without limitation, the award of attorneys’ fees to the prevailing Party,
shall be paid as the arbitrator determines.

 

12.9       Rights
and Remedies. The rights and remedies provided by this Agreement are cumulative, and the use of any one right or remedy by
any Party shall not preclude or waive the right to use any or all other remedies. Such rights and remedies are given in addition
to any other rights the Parties may have by law, statute, ordinance or otherwise.

 

12.10       Waiver.
No term of this Agreement can be waived except by the written consent of the Party waiving compliance. No waiver of a provision,
breach or default shall apply to any other provision or subsequent breach or default or be deemed continuous, nor will any single
or partial exercise of a right or power preclude any other further exercise of any rights or remedies provided by law or equity.

 

12.11       Severability.
In the event that any provision contained in this Agreement is determined to be invalid, void or illegal, such provision shall
be deemed deleted from the Agreement and shall not affect the validity of the remaining provisions of this Agreement.

 

12.12       Force
Majeure. No Party shall be liable for any failure to perform its obligations under this Agreement to the extent such
failure to perform is due to circumstances reasonably beyond such Party’s control, provided that the affected Party
uses reasonable efforts to overcome or avoid the effects of such cause and continues to perform its obligations to the extent
possible.

 

    Page 26 of 35

     

    

 

12.13       Survivability.
All rights and obligations of the Parties which by intent or meaning have validity beyond or by their nature apply or are to be
performed or exercised after the termination or expiration of this Agreement shall survive the termination or expiration of this
Agreement for the period so specified, if any, or for perpetuity.

 

12.14       Governing
Law. This Agreement, and the application or interpretation hereof, shall be governed exclusively by its terms and by the laws
of the State of Alabama.

 

12.15       Jurisdiction.
The Licensee consents on behalf of itself and its Affiliates to the personal jurisdiction of the federal and state courts located
in the State of Alabama with respect to all claims or other causes of action arising out of this Agreement.

 

12.16       Interpretation.
Whenever used in this Agreement and when required by the context, the singular number shall include the plural and the plural the
singular. Pronouns of one gender shall include all genders, masculine, feminine and neuter.

 

12.17       Captions.
The captions as to contents of particular sections or paragraphs contained in this Agreement are inserted for convenience and are
in no way to be construed as part of this Agreement or as a limitation on the scope of the particular sections or paragraphs to
which they refer.

 

12.18       Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall constitute one
and the same instrument.

 

 

The remainder of this page intentionally
left blank

 

    Page 27 of 35

     

    

 

IN WITNESS WHEREOF, the Licensee
and UABRF have each caused its duly authorized representative to execute this Agreement, effective as of the Effective Date.

 

	UABRF:	 	THE LICENSEE:
	The UAB Research Foundation 	 	Incysus, Ltd.
	 	 	 
	By:	/s/ Authorized Signatory	 	By:	/s/ William Ho
	 	 	Name: 	William Ho
	 	 	Title:	CEO

	 	 
	 	By:	   
	 	Name:	 
	 	Title:	 

 

	Addresses For Notices and Payments:	Address For Notices:
	
        For Delivery by Hand or Courier Service:

         

        The UAB Research Foundation

        Attention: Executive Director

        701 20th Street South

        Administration Building 770

        Birmingham, AL 35233

         

        For Delivery by U.S. Postal Service:

         

        The UAB Research Foundation

        Attention: Executive Director

        1720 2nd Avenue South

        Administration Building 770

        Birmingham, AL 35294-0107
	
        Incysus, Ltd.

        Clarendon House

        2 Church Street

        Hamilton, HM11

        Bermuda

         

         

 

    Page 28 of 35

     

    

 

EXHIBIT A

LICENSED PATENTS 

(dated as of the Effective Date)

 

[*****]

 

    Page 29 of 35

     

    

  

EXHIBIT B

DEVELOPMENT AND COMMERCIALIZATION PLAN

 

[*****]

 

    Page 30 of 35

     

    

 

EXHIBIT C

MILESTONES

 

[*****] 

 

    Page 31 of 35

     

    

 

 

EXHIBIT C 

(Continued)

 

 

[*****]

 

    Page 32 of 35

     

    

 

EXHIBIT D

FORM OF STOCK PURCHASE AGREEMENT

  

 

    Page 33 of 35

     

    

 

EXHIBIT E

FORM OF DEVELOPMENT AND COMMERICIALIZATION
PROGRESS REPORT

 

Licensee Name

Address

City, State,
Zip

 

Progress
Report covering the period January- December, 20__ for the License between Licensee and UABRF dated ________________

 

As required
under Article 3 of the above-referenced license agreement, the following details the progress made during the reporting period
in commercializing the licensed technology.

		§	[*****]

		§	[*****]

 

    Page 34 of 35

     

    

 

EXHIBIT F

RESEARCH PLAN 

 

The following research and development priorities will be addressed.

 

[*****]

 

    Page 35 of 35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]